<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7338588</article-id><article-id pub-id-type="doi">10.3389/fimmu.2020.01606</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Carter-Timofte</surname><given-names>Madalina Elena</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>J&#x000f8;rgensen</surname><given-names>Sofie Eg</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Freytag</surname><given-names>Mette Ratzer</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thomsen</surname><given-names>Michelle M&#x000f8;lgaard</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brinck Andersen</surname><given-names>Nanna-Sophie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Al-Mousawi</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hait</surname><given-names>Alon Schneider</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mogensen</surname><given-names>Trine H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/489790/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Biomedicine, Aarhus University</institution>, <addr-line>Aarhus</addr-line>, <country>Denmark</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Infectious Diseases, Aarhus University Hospital (AUH)</institution>, <addr-line>Aarhus</addr-line>, <country>Denmark</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Clinical Medicine</institution>, <addr-line>Aarhus</addr-line>, <country>Denmark</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Anne Puel, Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale (INSERM), France</p></fn><fn fn-type="edited-by"><p>Reviewed by: Sergio Rosenzweig, National Institutes of Health (NIH), United States; Carlos Rodr&#x000ed;guez Gallego, University Hospital of Gran Canaria Dr. Negrin, Spain</p></fn><corresp id="c001">*Correspondence: Trine H. Mogensen <email>trine.mogensen@biomed.au.dk</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Primary Immunodeficiencies, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>6</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>11</volume><elocation-id>1606</elocation-id><history><date date-type="received"><day>08</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Carter-Timofte, J&#x000f8;rgensen, Freytag, Thomsen, Brinck Andersen, Al-Mousawi, Hait and Mogensen.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Carter-Timofte, J&#x000f8;rgensen, Freytag, Thomsen, Brinck Andersen, Al-Mousawi, Hait and Mogensen</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Coronavirus disease-19 (COVID-19) describes a set of symptoms that develop following infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Whilst COVID-19 disease is most serious in patients with significant co-morbidities, the reason for healthy individuals succumbing to fulminant infection is largely unexplained. In this review, we discuss the most recent findings in terms of clinical features and the host immune response, and suggest candidate immune pathways that may be compromised in otherwise healthy individuals with fulminating COVID-19. On the basis of this early knowledge we reason a potential genetic effect on host immune response pathways leading to increased susceptibility to SARS-CoV-2 infection. Understanding these pathways may help not only in unraveling disease pathogenesis, but also in suggesting targets for therapy and prophylaxis. Importantly such insight should instruct efforts to identify those at increased risk in order to institute preventative measures, such as prophylactic medication and/or vaccination, when such opportunities arise in the later phases of the current pandemic or during future similar pandemics.</p></abstract><kwd-group><kwd>SARS-coronavirus 2</kwd><kwd>host immune defenses</kwd><kwd>immunopathology</kwd><kwd>innate immunity</kwd><kwd>primary immunodeficiency</kwd><kwd>whole exome sequencing</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Det Frie Forskningsr&#x000e5;d<named-content content-type="fundref-id">10.13039/501100004836</named-content></funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="0"/><equation-count count="0"/><ref-count count="213"/><page-count count="14"/><word-count count="13013"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>In late December 2019, several cases of acute respiratory distress syndrome (ARDS) were reported across several provinces in China, and by March 2020, the World Health Organization (WHO) declared the current outbreak a global pandemic (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Six zoonotic coronaviruses are known to have the capability to cause respiratory disease in humans. The human coronaviruses (HCoV) 229E, NL63, OC43, and HKU1 are identified as weakly pathogenic, causing mild upper respiratory disease (<xref rid="B3" ref-type="bibr">3</xref>). However, during the last two decades, public health has been threatened by two highly pathogenic coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, and Middle-East respiratory coronavirus, (MERS-CoV) in 2012 (<xref rid="B4" ref-type="bibr">4</xref>). The 2019/20 outbreak was rapidly identified to be caused by a new member of the coronavirus family, namely SARS-CoV-2. This virus spreads by human-to-human transmission and early observational data has suggested a reproductive number of 2.2 days. Together with a mean incubation time of 5.2 days, SARS-CoV-2 has the ability to spread widely among humans (<xref rid="B5" ref-type="bibr">5</xref>). As of April 2020, ~8.9 million cases of coronavirus diseases (COVID-19) and 465,740 deaths have been reported globally according to the WHO. Whilst the majority of deaths have been of elderly individuals or patients with underlying health conditions, a small number of young and healthy people have also succumbed to fulminant infection. In these rare cases, host genetics may provide some explanation for failure to control SARS-CoV-2 infection.</p><p>Primary immunodeficiencies (PIDs) are a group of genetically determined diseases predisposing individuals to severe infection, immune dysregulation, autoimmunity and malignancy (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). There is increasing evidence that the extreme variability in the clinical outcome of infections can often be influenced by the germ line genetics of the human host (<xref rid="B8" ref-type="bibr">8</xref>). Such monogenic inborn errors of immunity predispose to a narrow or broad range of viral infections (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Examples include herpes simplex virus encephalitis and defects in the TLR3 pathway and RNA metabolism (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>), varicella-zoster virus and defective innate RNA POL III signaling (<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>), severe influenza and defects in IRF7 (<xref rid="B16" ref-type="bibr">16</xref>), IRF9 (<xref rid="B17" ref-type="bibr">17</xref>), TLR3 (<xref rid="B18" ref-type="bibr">18</xref>), GATA2 (<xref rid="B19" ref-type="bibr">19</xref>), and RIG-I (<xref rid="B20" ref-type="bibr">20</xref>), rhinovirus infection and MDA5 (<xref rid="B21" ref-type="bibr">21</xref>), papillomaviruses and mutations in EVER1/2 (<xref rid="B22" ref-type="bibr">22</xref>), EBV lymphoproliferation and malignancy in the case of defects in SH2D1A (<xref rid="B23" ref-type="bibr">23</xref>), CD27, CD70 (<xref rid="B24" ref-type="bibr">24</xref>), XIAP (<xref rid="B25" ref-type="bibr">25</xref>), ITK (<xref rid="B26" ref-type="bibr">26</xref>), and MAGT1 (<xref rid="B27" ref-type="bibr">27</xref>), fatal CMV infection in NOS2 deficiency (<xref rid="B28" ref-type="bibr">28</xref>), and finally disseminated infection with measles vaccine strain virus in IFNAR and STAT2 deficiency (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). In this review, we aim to discuss the most recent findings in terms of the innate and adaptive immune response to SARS-CoV-2, and draw on knowledge from the previous SARS-CoV and MERS-CoV outbreaks where relevant. This knowledge should enable us to speculate and to suggest essential antiviral pathways that may be defective in individuals at increased risk of severe COVID-19 and thus suggest genetic etiologies which may predispose otherwise healthy individuals without comorbidities to severe SARS-CoV-2 infection.</p></sec><sec id="s2"><title>Clinical Presentations of COVID-19</title><p>The severity of COVID-19 is extremely variable, with some individuals reporting almost no symptoms, whereas others become critically ill requiring intensive care and respiratory ventilation (<xref rid="B31" ref-type="bibr">31</xref>&#x02013;<xref rid="B33" ref-type="bibr">33</xref>). The frequency of asymptomatic infections is yet to be determined and the differentiation between those and pre-symptomatic cases should be considered (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). In the largest case report of 44,672 confirmed cases of COVID-19 described by the Chinese CDC, an overall case fatality rate (CFR) of 2.3% was calculated (<xref rid="B36" ref-type="bibr">36</xref>). However, the mortality rates vary widely between different ages. No deaths were reported in children &#x0003c;9 years old, but the CFR increases to 14.8% in the 80+ age group. In critical cases requiring ventilator support in the ICU, a CFR of 49&#x02013;61% was reported (<xref rid="B36" ref-type="bibr">36</xref>). Whilst severe disease outcomes have been reported in otherwise healthy individuals of any age, several risk factors are recognized that lead to a more critical disease course; these include old age, hypertension, diabetes, obesity, cardiovascular, pulmonary, and cerebrovascular disease (<xref rid="B37" ref-type="bibr">37</xref>).</p><p>COVID-19 initially presents with non-specific signs and symptoms of upper airway viral infection characterized by fever, fatigue, cough, and dyspnoea, as well as anorexia, myalgia, and productive sputum, which can develop to pneumonia (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B38" ref-type="bibr">38</xref>). Intriguingly, patients are increasingly reporting anosmia and dysgeusia, the loss of smell and taste, reflecting some neurological effect of SARS-CoV-2 (<xref rid="B39" ref-type="bibr">39</xref>), which has subsequently been confirmed by several reports of central and peripheral nervous system manifestations, with meningitis, encephalitis, myelitis, and Guillain-Barre syndrome presenting as components of severe COVID-19 (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). In this context, respiratory failure has been hypothesized to be partly neurogenic in origin and possibly resulting from viral invasion of cranial nerve I into brainstem respiratory centers (<xref rid="B41" ref-type="bibr">41</xref>). Gastrointestinal symptoms, particularly nausea, vomiting, and diarrhea, are commonly described (<xref rid="B42" ref-type="bibr">42</xref>). In the most critical cases, widespread lung inflammation can lead to acute respiratory distress syndrome (ARDS), which often necessitates mechanical ventilation or extracorporeal membrane oxygenation (ECMO) to prevent total respiratory failure (<xref rid="B43" ref-type="bibr">43</xref>). Recent studies have demonstrated an extensive tendency for coagulopathy, thrombosis, micro-thrombosis, and disseminated intravascular coagulation during severe COVID-19 (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>) which is reflected in elevated fibrin and D-dimer levels during disease (<xref rid="B46" ref-type="bibr">46</xref>). Furthermore, a significant fraction of deceased ICU patients have pulmonary thrombosis or deep vein thrombosis as revealed by autopsy results (<xref rid="B47" ref-type="bibr">47</xref>).</p><p>Several clinical and immunological studies have suggested that excessive inflammation and a cytokine storm play a key role in the immunopathology, responsible for much of the lung damage, morbidity and mortality in patients with severe COVID-19 in ICUs (<xref rid="B48" ref-type="bibr">48</xref>&#x02013;<xref rid="B50" ref-type="bibr">50</xref>). This concept opens up the possibility that medical treatments that dampen immune activation may represent an important strategy in treating this disease and decreasing the high mortality (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>). Finally, there is emerging evidence that some infants and children have presented with a clinical picture of auto-inflammation and vasculitis, diagnosed as atypical Kawasaki's disease (<xref rid="B53" ref-type="bibr">53</xref>), a rare disease entity causing systemic inflammation, fever, and vasculitis with a risk of developing aneurisms. This inflammatory condition associated with a previous SARS-CoV-2 infection has been named Pediatric Multisystem Inflammatory Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) (<xref rid="B54" ref-type="bibr">54</xref>).</p></sec><sec id="s3"><title>SARS-CoV-2</title><p>Coronaviruses are enveloped, positive-sense, single-stranded viruses that contain the largest genome amongst RNA viruses (27&#x02013;32 kb) (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). SARS-CoV-2 belongs to the <italic>Betacoronavirus</italic> genera, based on its phylogenetic relationship with other <italic>Betacoronaviruses</italic>, such as SARS-CoV and MERS-CoV (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>). Whilst SARS-CoV-2 shares 79% nucleotide sequence identity with SARS-CoV, Zhou et al. reported the SARS-CoV-2 sequence to be 96.2% identical to the sequence of the horseshoe bat coronavirus, RaTG13, suggesting that SARS-CoV-2 originates from this bat species (<xref rid="B58" ref-type="bibr">58</xref>). An intermediate animal host between horseshoe bats and humans, as well as the transmission route, has yet to be identified in the SARS-CoV-2 pandemic (<xref rid="B59" ref-type="bibr">59</xref>). However, the most prevalent hypothesis is that the virus acquired one or several mutations allowing it to cross species barriers and infect human cells some time in autumn 2019, a few months before the beginning of the current pandemic (<xref rid="B60" ref-type="bibr">60</xref>).</p><p>Like other coronaviruses, the major structural proteins of SARS-CoV-2 include the envelope (E), membrane (M) and spike (S) proteins (<xref rid="B61" ref-type="bibr">61</xref>). In the earlier SARS-CoV epidemic, the S protein was shown to facilitate cellular entry by binding to the angiotensin-converting enzyme 2 (ACE2) receptor present on target cells (<xref rid="B62" ref-type="bibr">62</xref>). In addition, the cellular serine protease transmembrane protease serine 2 (TMPSS2) is needed for priming of the S protein and subsequent fusion of SARS-CoV with the host cell membrane (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>). Furthermore, overexpression of ACE2 enhances disease severity in mice upon SARS-CoV infection, indicating the importance of this receptor in facilitating viral entry (<xref rid="B65" ref-type="bibr">65</xref>). Several studies have shown that the S protein of SARS-CoV-2 also uses ACE2 and TMPRSS2 for cell entry, and that the SARS-CoV-2 S protein is able to bind to ACE2 with 10- to 20-fold higher affinity than the SARS-CoV S protein (<xref rid="B66" ref-type="bibr">66</xref>&#x02013;<xref rid="B69" ref-type="bibr">69</xref>). Furthermore, ACE2 is highly expressed by type II alveolar epithelial cells (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>) which correlates with the pulmonary symptoms of COVID-19 (<xref rid="B32" ref-type="bibr">32</xref>). However, ACE2 is also highly expressed by intestinal, heart, kidney and bladder cells (<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>). This pattern of cellular ACE2 expression may explain some of the non-respiratory symptoms and complications that SARS-CoV-2 patients exhibit, such as diarrhea, kidney failure and cardiac injury (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B73" ref-type="bibr">73</xref>).</p></sec><sec id="s4"><title>Innate Immune Responses to SARS-CoV-2</title><p>The innate immune response is the first line of defense against a wide range of pathogens, particularly viruses. Importantly, viral infection induces type I interferons (IFN) (IFN&#x003b1;/&#x003b2;) and type III IFNs (IFN-&#x003bb;), which activate hundreds of antiviral proteins as well as mediate priming the adaptive immune response (<xref ref-type="fig" rid="F1">Figure 1</xref>). Coronaviruses, and their nucleic acid genome and replication intermediates in particular, are recognized primarily by two groups of pattern recognition receptors, namely the Toll-like receptors (TLRs) and the retinoic acid inducible gene I (RIG-I)-like receptors (RLRs). These receptors recognize several viral components, which induce downstream signaling and result in production of antiviral type I and III IFNs as well as proinflammatory cytokines through activation of the transcription factors interferon regulatory factor (IRF)3, IRF7 and nuclear factor(NF)-&#x003ba;B (<xref rid="B74" ref-type="bibr">74</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Induction of interferons (IFN) and signaling by the type I and III IFN receptors. The presence of microbial or self nucleic acid in the cytosol or within the endosomal compartment activates pattern recognition receptors (PRR)s. RNA activates retinoic acid-inducible receptor (RIG)-I in the cytosol and Toll-like receptor (TLR)3 and TLR7 in the endosomal compartment. These events trigger signaling pathways through the adaptor molecules mitochondrial antiviral signaling protein (MAVS), TIR-domain-containing adapter-inducing interferon-&#x003b2; (TRIF), and Myeloid differentiation primary response (MyD)88 leading to phosphorylation and activation of the TANK binding kinase (TBK)1, which in turn phosphorylates the transcription factors IFN regulatory factor (IRF)3 and IRF7. Whereas IRF3 is constitutively present, IRF7 is only expressed at low levels but may be secondarily induced by Type I IFN. Phosphorylation of IRF3 and IRF7 leads to homodimerization, nuclear translocation, and expression of Type I IFNs (IFN&#x003b1; and IFN&#x003b2;) and type III IFNs (IFN&#x003bb;) acting on neighboring cells with type I and III IFN receptors, respectively. Type I IFN binds to IFN&#x003b1;/&#x003b2; receptor composed of IRFNAR1 and IFNAR2, whereas type III IFN binds to the IFN&#x003bb; receptor composed of IFNLR1 and IL10R&#x003b2;. These events activate the downstream receptor-associated Janus-associated kinase (JAK)1 and tyrosine kinase (TYK)2 and subsequent tyrosine phosphorylation of STAT1 and STAT2. These activated transcription factors together with IRF9 form the heterotrimeric transcription factor IFN-stimulated gene factor (ISGF)3 complex which binds to IFN-stimulated regulatory elements (ISRE) in DNA. In addition, STAT1 homodimers form the IFN-&#x003b3;-activated factor (GAF) complex which binds to &#x003b3;-activated (GAS) sequences. Altogether, these transcription factors induce a broad spectrum of IFN-stimulated genes (ISG)s that mediate the complex &#x0201c;antiviral state&#x0201d; of IFNs.</p></caption><graphic xlink:href="fimmu-11-01606-g0001"/></fig><p>The TLRs which have so far been implicated in the response to SARS-CoV, are TLR3, -4 and -7 (<xref ref-type="fig" rid="F2">Figure 2</xref>). TLR3 recognizes double-stranded RNA (dsRNA), and the coronavirus-derived ligand is likely a double-stranded replication intermediate. The ligand for TLR4 remains obscure, as TLR4 usually recognizes lipopolysaccharide from gram negative bacteria. Finally, special GU-rich sequences in the SARS-CoV genome activate TLR7 (<xref rid="B75" ref-type="bibr">75</xref>). TLR3 and TLR4 activate the adaptor TIR-domain-containing adapter-inducing interferon-&#x003b2; (TRIF), whereas myeloid differentiation primary response 88 (MyD88) is the adaptor used by all other TLRs (<xref rid="B76" ref-type="bibr">76</xref>) (<xref ref-type="fig" rid="F2">Figure 2</xref>). Insights from mouse knock-out studies may provide some knowledge as to which signaling pathways are important in SARS-CoV-2 recognition, and where we might expect to identify genetic variants, which predispose to more severe COVID-19 disease.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Innate immune signaling pathways that are known to be activated during viral infection and replication. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects human cells through the angiotensin-converting enzyme 2 (ACE2 receptor) and the cellular serine protease TMPRSS2 for viral S protein priming. Following cellular entry, the virus RNA genome may be recognized by pattern recognition receptors (PRR)s, including endosomal Toll-like receptor (TLR)3 and TLR7 recognizing double-stranded and single-stranded RNA, respectively. In the cytosol the virus may be recognized by the retinoic acid inducible receptor (RIG)-I or the melanoma differentiation-associated protein (MDA)5. Following viral recognition by PRRs, this triggers signaling through IFN regulatory factor (IRF)3 and NF-&#x003ba;B to induce IFNs and pro-inflammatory cytokines. Similar responses may be activated by extracellular virus through TLR4.</p></caption><graphic xlink:href="fimmu-11-01606-g0002"/></fig><p>Several studies have demonstrated that infection of <italic>Tlr3</italic><sup>&#x02212;/</sup><sup>&#x02212;</sup>, <italic>Tlr4</italic><sup>&#x02212;/&#x02212;</sup><italic>, Trif</italic><sup>&#x02212;/&#x02212;</sup><italic>, Tram</italic><sup>&#x02212;/&#x02212;</sup>, and <italic>Myd88</italic><sup>&#x02212;/&#x02212;</sup> mice with SARS-CoV causes increased viral replication, enhanced pathology in the lungs, and increased morbidity (<xref rid="B77" ref-type="bibr">77</xref>&#x02013;<xref rid="B79" ref-type="bibr">79</xref>). The most severe phenotypes and mortality are generally seen in mice lacking the downstream adaptors TRIF and MyD88 (<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>). Interestingly, following SARS-CoV infection of <italic>Trif</italic><sup>&#x02212;/&#x02212;</sup> mice, the aberrant proinflammatory cytokine and chemokine responses were similar to those seen in human patients with poor disease outcome during SARS-CoV infection (<xref rid="B80" ref-type="bibr">80</xref>) or MERS-CoV infection (<xref rid="B81" ref-type="bibr">81</xref>). This may suggest that the initial impaired control of viral replication could lead to exaggerated immune responses and enhanced immunopathology later during infection. However, MyD88 and IRAK4 seem to be largely redundant in antiviral immunity in humans, since previous studies have failed to report increased susceptibility to severe viral infection in patients deficient in these molecules (<xref rid="B82" ref-type="bibr">82</xref>). This underlines the value of studying the spectrum of infections in patients with well-defined immunodeficiencies <italic>in natura</italic>, revealing important lessons on protective immunity in humans (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B83" ref-type="bibr">83</xref>).</p><p>Coronaviruses are, in addition to being recognition by TLRs, also recognized by RLRs. The RLRs are cytosolic RNA sensors, where RIG-I recognizes short dsRNA with 5' triphosphate, and melanoma differentiation-associated protein 5 (MDA5) recognizes long dsRNA. MDA5 is clearly protective in mice infected with the murine coronavirus mouse hepatitis virus (MHV) (<xref rid="B84" ref-type="bibr">84</xref>), whereas there are only limited reports indicating that the other RLRs are important in SARS-CoV infection. This is, however, not due to the virus failing to be recognized by the receptors, but rather because SARS-CoV, as well as other coronaviruses, employs several strategies to avoid recognition and immune activation. For example, deletion of the SARS-CoV nsp16 gene, an enzyme which catalyzes ribose 2'-O-methylation to generate caps on the coronavirus RNA (<xref rid="B85" ref-type="bibr">85</xref>), attenuates the pathogenicity of the virus (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B87" ref-type="bibr">87</xref>). However, in the absence of MDA5 or Interferon Induced Protein With Tetratricopeptide Repeats 1 (IFIT1), the SARS-CoV nsp16 deletion mutant reached similar levels of viral replication and virulence as wild type SARS-CoV (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B87" ref-type="bibr">87</xref>), indicating that MDA5 recognizes partly uncapped SARS-CoV RNA. The recognition of SARS-CoV by RIG-I has not yet been described, probably due to the fact that RIG-I has a preference for short dsRNA and also because the initial steps of capping impairs RIG-I recognition by removing the 5'triphosphate (<xref rid="B85" ref-type="bibr">85</xref>).</p><p>Investigations into the role of lung inflammation during respiratory infection identified a potential role for excessive inflammasome activation. Mice in which the inflammasome pathway had been deleted by CASP1/11 knock-out displayed less mortality upon influenza infection compared to wild-type mice (<xref rid="B88" ref-type="bibr">88</xref>). Furthermore, inflammation was shown to be driven by excessive neutrophil activation. Given that neutrophilia is a paraclinical indication of COVID-19 disease severity, we might predict that inhibiting this response may improve outcomes in SARS-CoV-2 infection. These studies are supported by other data demonstrating that the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome activation by the SARS-CoV viral proteins, E, ORF-8b and viroporin 3a (<xref rid="B89" ref-type="bibr">89</xref>&#x02013;<xref rid="B91" ref-type="bibr">91</xref>). Importantly, coronaviruses can induce pyroptosis via NLRP3 in a process involving insertion of Gasdermin D in the cellular membrane (<xref rid="B92" ref-type="bibr">92</xref>). Furthermore, several publications have implicated neutrophils and neutrophil extracellular traps (NET) in organ damage, pulmonary pathology, micro-thrombosis, and mortality in COVID-19 (<xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B94" ref-type="bibr">94</xref>). NETs consist of extracellular webs of chromatin, microbicidal proteins and oxidant enzymes that are released by neutrophils to contain microbial infections but also have the potential to propagate inflammation and immunopathology (<xref rid="B94" ref-type="bibr">94</xref>).</p><p>IFNs are the most prominent antiviral effectors of the innate immune system, and SARS-CoV infection is highly susceptible to this potent antiviral substance, as shown by the efficient inhibition of viral replication upon administration of exogenous IFN both <italic>in vitro</italic> and <italic>in vivo</italic> (<xref rid="B95" ref-type="bibr">95</xref>&#x02013;<xref rid="B100" ref-type="bibr">100</xref>). However, only very limited amounts of IFNs are actually produced during SARS-CoV and MERS-CoV infections (<xref rid="B101" ref-type="bibr">101</xref>), and the response seems to be delayed relative to the production of proinflammatory cytokines (<xref rid="B102" ref-type="bibr">102</xref>). However, it is worth noting that these anti-viral responses are most likely cell-type specific. A recent study demonstrated that SARS-CoV-2 also induces significantly less alveolar cell IFN and ISG expression compared to influenza A and respiratory syncytial virus <italic>in vitro</italic> (<xref rid="B103" ref-type="bibr">103</xref>). In support of these data, a comparative study reported more efficient viral replication and a reduced type I IFN response in SARS-CoV-2 infection of <italic>ex-vivo</italic> human lung cultures compared to SARS-CoV (<xref rid="B104" ref-type="bibr">104</xref>). To achieve this very low IFN production, the coronaviruses are known to employ numerous strategies to counteract the innate immune signaling pathways of the host, which have been reviewed elsewhere (<xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B105" ref-type="bibr">105</xref>&#x02013;<xref rid="B107" ref-type="bibr">107</xref>). However, the exact mechanisms by which SARS-CoV-2 appears to more efficiently prevent IFN production, and if this is partly responsible for increased pathogenicity in the current outbreak, remains elusive. Collectively, future identification of the molecules and signaling pathways targeted by SARS-CoV-2 will provide essential information on key antiviral modalities, which may also be those defective in patients with genetic predisposition to severe disseminated COVID-19.</p></sec><sec id="s5"><title>Adaptive Immune Responses to SARS-CoV-2</title><p>The cell-mediated immune response plays a critical role in antiviral immunity, and developing early and robust CD8<sup>+</sup> and in particular, CD4<sup>+</sup> T cell responses correlates well with positive outcomes during SARS-CoV infection (<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B109" ref-type="bibr">109</xref>). Clinical investigations of severe COVID-19 patients consistently report neutrophilia and lymphopenia, with significantly depressed CD4<sup>+</sup> T cell counts and decreased IFN-&#x003b3; expression, as well as reduced numbers of regulatory and memory T cells (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B110" ref-type="bibr">110</xref>, <xref rid="B111" ref-type="bibr">111</xref>). In addition, increased levels of plasma pro-inflammatory cytokines such as Interleukin (IL)-1&#x003b2;, IL-6, IL-8, and tumor necrosis factor-&#x003b1; (TNF-a) are observed in severe COVID-19 patients, indicative of a cytokine storm and subsequent ARDS development (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B73" ref-type="bibr">73</xref>). In support of these data, a study of 522 hospitalized COVID-19 patients reported a negative correlation between T cell numbers and serum IL-6, IL-10 and TNF-&#x003b1; levels (<xref rid="B112" ref-type="bibr">112</xref>). Furthermore, COVID-19 patients displayed increased expression of the T cell exhaustion markers, programmed cell death protein-1 (PD-1) and Tim-3, compared to healthy controls, suggesting that T cell survival and activation may play a role in protecting the host from severe SARS-CoV-2 development (<xref rid="B112" ref-type="bibr">112</xref>, <xref rid="B113" ref-type="bibr">113</xref>). Studies investigating T cell phenotypes in asymptomatic or convalescent COVID-19 patients have been more limited. However, a recent study (<xref rid="B114" ref-type="bibr">114</xref>) identified circulating SARS-CoV-2-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells in ~70% and 100% of recovered COVID-19 patients, respectively. Importantly, this study reported the presence of SARS-CoV-2-reactive CD4<sup>+</sup> T cells in healthy donors recruited in 2015&#x02013;2018 (<xref rid="B114" ref-type="bibr">114</xref>). These data suggest that there is a cross-reactive coronavirus T cell memory response, but whether such pre-existing immunity influences clinical outcomes remains to be determined.</p><p>Cytotoxic T cells are important for clearing respiratory viruses and providing long-term protection; however, the magnitude of this response must be well-controlled to prevent pathological consequences (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B115" ref-type="bibr">115</xref>). Histological examination of a patient who died from severe SARS-CoV-2 infection identified that whilst the overall peripheral CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts were significantly reduced, alveolar CD8<sup>+</sup> T cells harbored high concentrations of cytotoxic granules, which may have contributed to severe tissue injury (<xref rid="B116" ref-type="bibr">116</xref>). Moreover, lung biopsy revealed desquamation of pneumocytes, pulmonary oedema, and hyaline membrane formation, indicative of early-stage ARDS development (<xref rid="B116" ref-type="bibr">116</xref>). On the other hand, a robust CD8<sup>+</sup> T cell response is known to be important in SARS-CoV infection, and mild cases of COVID-19 have increased clonal expansion of CD8<sup>+</sup> T cells, compared to severe cases (<xref rid="B117" ref-type="bibr">117</xref>). The pathological features of COVID-19 resemble those of SARS and MERS, both of which are thought to be largely caused by immune dysregulation rather than direct pathology induced by high viral load (<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B118" ref-type="bibr">118</xref>), with a similar picture emerging for SARS-CoV-2.</p><p>A considerable number of studies have demonstrated that infection with SARS-CoV-2 initiates an antibody response. On average, seroconversion is observed between 10 and 14 days post infection, a timeline similar to that observed for the previous SARS-CoV epidemic (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B119" ref-type="bibr">119</xref>&#x02013;<xref rid="B123" ref-type="bibr">123</xref>). Serological investigations of 262 hospitalized COVID-19 patients across the Chongqing region, China, reported simultaneous or sequential seroconversion (IgM and IgG) against recombinant antigens containing the nucleoprotein and a peptide from the spike protein of SARS-CoV-2 (<xref rid="B124" ref-type="bibr">124</xref>). Interestingly, IgG titers were higher in patients with severe COVID-19, compared to the non-severe group (<xref rid="B124" ref-type="bibr">124</xref>). A number of studies have also reported earlier or increased antibody titers in critical vs. non-critical COVID-19 patients, possibly reflecting more severe and invasive infection and thus making it difficult to determine the specific nature of the association (<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B125" ref-type="bibr">125</xref>) whereas others report no correlation between disease severity and serum antibody levels (<xref rid="B126" ref-type="bibr">126</xref>). Such discrepancies between findings may be explained not only by the relatively small number of individuals investigated per study, but also due to the fact that different assays are used in the different studies, likely causing significant sensitivity and specificity challenges (<xref rid="B123" ref-type="bibr">123</xref>). Importantly, however, SARS-CoV-2 isolated from critically ill patients can be neutralized by sera from several patients, a finding that gives weight to the rapid development of therapeutic neutralizing antibodies (NAbs) as a potential means to control the current pandemic (<xref rid="B58" ref-type="bibr">58</xref>).</p><p>The possibility of re-infection with SARS-CoV-2 is a key area of investigation. Individuals who recovered from SARS-CoV or MERS-CoV infection displayed high tires of antibodies which waned after 2&#x02013;3 years (<xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B128" ref-type="bibr">128</xref>). However, a small study of only three SARS-recovered individuals identified SARS-specific memory T cells 11 years after infection (<xref rid="B129" ref-type="bibr">129</xref>). Finally, the efficacy and longevity of immunity to SARS-CoV-2 is highly dependent upon the rate by which the virus alters its composition, i.e., the mutation rate. So far, studies suggest a relatively low virus mutation rate with mutations randomly spread throughout the viral genome, suggesting absence of positive selection toward increased virulence (<xref rid="B60" ref-type="bibr">60</xref>). Moreover, previous studies suggest that a virus crossing the species barrier is more likely to lose virulence over time than the opposite (<xref rid="B130" ref-type="bibr">130</xref>).</p></sec><sec id="s6"><title>Human Inborn Errors of Immunity Predisposing to Coronavirus Infection</title><p>Several predisposing factors are known to increase the risk of progression to severe COVID-19 (<xref rid="B37" ref-type="bibr">37</xref>). However, there is currently no explanation as to why younger individuals with no co-morbidities in rare cases have developed life-threatening COVID-19. Human inborn errors of immunity can alter the course of various viral infections (<xref rid="B131" ref-type="bibr">131</xref>), but in the case of disease progression in SARS-CoV-2 infection, little is known regarding the influence of the host genetic makeup. However, any genetic variant that results in a dysregulated or exaggerated immune response may contribute to lung immunopathology leading to life-threatening clinical manifestations.</p><p>It has been proposed that deficient type I IFN production may undermine the innate immune response during early SARS-CoV infection, resulting in a more severe disease course (<xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B132" ref-type="bibr">132</xref>, <xref rid="B133" ref-type="bibr">133</xref>). Population studies have identified single nucleotide polymorphisms (SNPs) in the IFN-inducible genes <italic>OAS1</italic> and <italic>MX1</italic>, associated with susceptibility to SARS-CoV infection and disease progression (<xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B135" ref-type="bibr">135</xref>). Moreover, exogenous administration of type I IFN has been shown to inhibit SARS-CoV replication both <italic>in vivo</italic> (<xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B99" ref-type="bibr">99</xref>) and <italic>in vitro</italic> (<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B100" ref-type="bibr">100</xref>). Together, these data highlight the importance of an intact type I IFN pathway in the innate response to SARS-CoV, and it can be reasoned that any genetic mutations that impair this response may somehow predispose to COVID-19 disease progression. Consequently, it is worth considering that clinical outcome may be influenced by mutations of the PRRs and immune signaling pathways involved in recognition of SARS-CoV-2, including RIG-I, MDA5, and TLR3 and downstream IRF3 and IRF7, as well as molecules involved in effector function of type I and III IFN, such as IFNAR1/2 or the janus kinase (JAK) - signal transducer and activator of transcription (STAT) signaling pathways.</p><p>Emerging evidence suggests that activation of the complement system contributes to the pathogenesis of SARS-CoV-2 lung pathology (<xref rid="B136" ref-type="bibr">136</xref>, <xref rid="B137" ref-type="bibr">137</xref>). Inhibition of the terminal complement pathway by targeting complement protein 5 (C5) has been proposed as an effective therapeutic intervention in CoV-mediated disease (<xref rid="B138" ref-type="bibr">138</xref>). Mannose-binding lectin (MBL) is a pattern recognition molecule, which binds to specific carbohydrate structures on the microbial surface, thereby activating complement terminal pathways (<xref rid="B139" ref-type="bibr">139</xref>). MBL serum immunodeficiency has been suggested to play a role, although controversial, in increased susceptibility to a wide range of viral and bacterial infections, mainly in children (<xref rid="B140" ref-type="bibr">140</xref>&#x02013;<xref rid="B142" ref-type="bibr">142</xref>). A single study has identified that individuals carrying a low MBL-producing haplotype YB have an increased risk of acquiring SARS-CoV (<xref rid="B143" ref-type="bibr">143</xref>). Collectively, the precise role of the complement system as either having a detrimental or protective role in COVID-19 pathogenesis needs further study.</p><p>Within adaptive immunity, the impact of PIDs associated with antibody deficiencies and combined immunodeficiencies on SARS-CoV-2 outcomes are not fully clarified. However, some important information may be retrieved from a description of severe lung pathology and COVID-19 disease course in patients with common variable immunodeficiency (CVID) compared to patients with pure agammaglobulinemia (<xref rid="B144" ref-type="bibr">144</xref>). Although the results were based on few patients, it was noted that patients with agammaglobulinemia experienced relatively mild disease. However, patients with similarly low immunoglobulin levels but immune dysregulation as part of CVID experienced more severe disease, suggesting a role of immune dysregulation and abnormal B immune cell phenotype and potentially excessive IL-6 production in COVID-19 pathogenesis, although T cell deficiency may also be involved (<xref rid="B144" ref-type="bibr">144</xref>). Collectively, results of studies into COVID-19 disease presentation and progression in patients with known PIDs are eagerly awaited. Such data may facilitate understanding of what constitutes an inadequate immune response toward SARS-CoV-2 and from this knowledge determine the molecular and cellular correlates of protective immune responses and immunity in COVID-19.</p><p>As to the role of T cells in protection from severe COVID-19, it would be expected that T cell lymphopenia from any source might represent an increased risk of severe viral infection. However, not much evidence suggests that patients with primary T cell defects nor HIV infection are at a significantly elevated risk. When large cohort studies of SARS-infected and MERS-CoV-infected patients from previous epidemics were reviewed, HIV infection was not identified as an independent risk factor for infection by these coronaviruses (<xref rid="B145" ref-type="bibr">145</xref>, <xref rid="B146" ref-type="bibr">146</xref>). However, evidence for the role of T cell defects on prevalence and severity of COVID-19 is scarce, and it is therefore too early to draw any conclusions (<xref rid="B147" ref-type="bibr">147</xref>).</p><p>Based on insight into immunopathogenesis and pathology during COVID-19, potential susceptibility genes may be involved in mechanisms of immune dysregulation, auto-inflammation or autoimmunity, thus involving the gain-of-function or loss of inhibition of various genes and pathways in cytokine and TLR signaling cascades, especially those affecting IL-1 and IL-6 synthesis and production (<xref rid="B48" ref-type="bibr">48</xref>&#x02013;<xref rid="B50" ref-type="bibr">50</xref>). Likewise, genetic variants in endothelial cell biology and regulation may be anticipated to aggravate coagulopathy and thrombotic events. Specific evidence on such associations remains to be reported but should be part of searches in large unbiased whole exome sequencing approaches, such as the worldwide consortium (<xref rid="B148" ref-type="bibr">148</xref>) (<ext-link ext-link-type="uri" xlink:href="http://www.covidhge.com">covidhge.com</ext-link>).</p><p>Genetic variants in the major histocompatibility complex antigen loci (HLA) are well-known to influence host susceptibility to infectious disease (<xref rid="B149" ref-type="bibr">149</xref>). So far, only a limited number of studies have looked for an association between HLA haplotypes and genetic susceptibility or resistance to SARS coronavirus infection. However, an impact of HLA haplotypes may identify some of the unexplained differences in disease severity and mortality observed across different countries and different population ethnicities (<xref rid="B150" ref-type="bibr">150</xref>&#x02013;<xref rid="B154" ref-type="bibr">154</xref>). Allele typing of 37 probable SARS patients in Taiwan identified an association between HLA-B<sup>*</sup>4601 and SARS-CoV infection (<xref rid="B155" ref-type="bibr">155</xref>); however, this was not confirmed in a study of 90 serologically confirmed SARS-CoV patients in Hong Kong (<xref rid="B156" ref-type="bibr">156</xref>, <xref rid="B157" ref-type="bibr">157</xref>). The latter study instead identified an association between the HLA-B<sup>*</sup>0703 and HLA-DRB1<sup>*</sup>0301 genotypes and the development of SARS (<xref rid="B157" ref-type="bibr">157</xref>). In terms of the current pandemic, we might predict that genetic variations in the HLA molecules resulting in decreased binding specificities for SARS-CoV-2 peptides may confer a more severe COVID-19 disease course (<xref rid="B158" ref-type="bibr">158</xref>). Zhao et al. (<xref rid="B159" ref-type="bibr">159</xref>) investigated the relationship between ABO blood group and COVID-19 susceptibility in 2,173 Chinese patients. Interestingly, being of blood group A represented a higher risk for developing COVID-19 disease, whilst having blood group O was associated with a lower infection risk. A similar risk pattern for ABO blood groups has also been reported for the 2003 SARS-CoV outbreak (<xref rid="B160" ref-type="bibr">160</xref>); however, the exact mechanism of how blood group antigens might affect susceptibility remains to be clarified.</p><p>Genetic studies have identified polymorphisms in the <italic>IL28B</italic> gene which have been linked to hepatitis C virus (HCV) clearance (<xref rid="B161" ref-type="bibr">161</xref>). The product of this gene is type III IFN (IFN-&#x003bb;). Given that genetic variants in IFN-&#x003bb; appear to play an important role in the natural course of disease and severity during infection with HCV, it will be interesting to investigate if polymorphisms in the <italic>IL28B</italic> gene could also predispose to severe SARS-CoV-2 infection. Perhaps the most compelling reason to believe that genetic differences may account for the vast diversity in COVID-19 symptoms is a recent preprint study by British researchers who, using a mobile symptom tracker, recorded data from over 2.7 million app users. Analysis of same sex adult twins (<italic>n</italic> = 2,000<sup>+</sup>) showed that genetic factors accounted for 50% of the difference in COVID-19 symptoms (<xref rid="B162" ref-type="bibr">162</xref>). Although the results from the latter studies will need to be verified, these data highlight how genetic differences may explain the great variability in SARS-CoV-2 infection outcome.</p><p>As we start to gain further insight into the pathogenesis of severe COVID-19 and appreciate the major role played by inflammation and immunopathology, this raises the question as to whether there might be an increased risk of developing severe disease in certain individuals, and whether genes predisposing to those conditions should be investigated in a genetic approach. Such genes include <italic>NLRP1, NLRP3, CASP1, MEFV</italic>, and many others, which all encode proteins involved in inflammasome activation (<xref rid="B163" ref-type="bibr">163</xref>). Focus should also be on known genetic causes of hemophagocytic lymphohistiocytosis (HLH), including defects in the genes <italic>PRF1, UNC13D, STX11, STXBP2, LYST, RAB27A</italic> (<xref rid="B164" ref-type="bibr">164</xref>) either in the well-recognized homozygous forms, or possibly in heterozygous forms that may still predispose to HLH in the presence of a trigger, such as SARS-CoV-2 (<xref rid="B165" ref-type="bibr">165</xref>). However, the precise pathogenesis of macrophage activation syndrome and Kawasaki-like disease/PIMS in COVID-19 is not fully understood and may involve autoinflammation, autoimmunity, and/or immunopathology induced directly by the virus or as a secondary result of crossreactivity.</p><p>At the other end of the disease spectrum, there is the possibility that some individuals may avoid infection due to protective tissue types or gene mutations. The most prominent example to mention is the potential protective role of ACE2 defects, rendering cells restistant to SARS-CoV-2 infection, in analogy to protection from HIV infection by Delta32 <italic>CCR5</italic> homozygosity (<xref rid="B166" ref-type="bibr">166</xref>). Given the important role of host ACE2 in SARS-CoV-2 infection, we might speculate that <italic>ACE2</italic> genetic polymorphisms may be present in certain individuals, which could be exploited by SARS-CoV-2 and lead to severe clinical disease. Equally, <italic>ACE2</italic> polymorphisms may even offer some level of resistance. Indeed, one study has identified multiple rare genetic variants in <italic>ACE2</italic>, which are predicted to modify virus-host interaction and alter susceptibility to SARS-CoV-2 (<xref rid="B167" ref-type="bibr">167</xref>). Another study has also reported rare, genetic variants in <italic>TMPRSS2</italic> as possible disease modulators of SARS-CoV-2 infection in Italy (<xref rid="B168" ref-type="bibr">168</xref>). Although these findings necessitate functional validation, it gives weight to the hypothesis that rare, genetic mutations may explain COVID-19 disease severity.</p></sec><sec id="s7"><title>Therapeutic Developments and Trials</title><p>No therapeutics have yet been approved to treat diseases caused by SARS-CoV-2 or other coronaviruses (<xref rid="B169" ref-type="bibr">169</xref>, <xref rid="B170" ref-type="bibr">170</xref>). By mid March 2020, WHO launched the global &#x0201c;Solidarity&#x0201d; clinical trial for COVID-19 treatments to assess the effectiveness of four potential therapeutic options, namely remdesivir, lopinavir/ritonavir with and without IFN-&#x003b2;, and chloroquine or hydroxychloroquine (<xref rid="B171" ref-type="bibr">171</xref>). Remdesivir, already early suggested to be the most promising compound (<xref rid="B172" ref-type="bibr">172</xref>, <xref rid="B173" ref-type="bibr">173</xref>), is a pro-drug of an adenosine nucleotide analog, which upon incorporation in the growing RNA chain potently inhibits RNA-dependent RNA polymerases inducing synthesis arrest (<xref rid="B172" ref-type="bibr">172</xref>, <xref rid="B174" ref-type="bibr">174</xref>). Remdesivir has broad antiviral activity against several RNA viruses <italic>in vitro</italic>, including SARS-CoV-2 (<xref rid="B174" ref-type="bibr">174</xref>&#x02013;<xref rid="B177" ref-type="bibr">177</xref>), and <italic>in vivo</italic> against SARS-CoV and MERS-CoV (<xref rid="B176" ref-type="bibr">176</xref>, <xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B179" ref-type="bibr">179</xref>). Whereas no significant improvement was observed in an initial trial of 237 patients receiving remdesivir (<xref rid="B180" ref-type="bibr">180</xref>), preliminary results from the larger Adaptive Covid-19 Treatment Trial (ACTT) showed that remdesivir significantly shortened the time to recovery in patients with lower airway involvement, and interestingly, another study found no difference between treatment with remdesivir for 5 days compared to 10 days (<xref rid="B181" ref-type="bibr">181</xref>, <xref rid="B182" ref-type="bibr">182</xref>). However, importantly, remdesivir did not show major efficacy in patients with severe COVID-19 in the ICU (<xref rid="B183" ref-type="bibr">183</xref>), possibly because host responses may be major determinants at that stage, rather than viral replication. Promising results in controlling SARS-CoV-2 <italic>in vitro</italic> have also been demonstrated for the protease inhibitor lopinavir/ritonavir, licensed for HIV treatment (<xref rid="B184" ref-type="bibr">184</xref>, <xref rid="B185" ref-type="bibr">185</xref>), as well as for chloroquine and hydroxychloroquine presently used in the treatment of malaria and autoimmune diseases (<xref rid="B175" ref-type="bibr">175</xref>, <xref rid="B186" ref-type="bibr">186</xref>, <xref rid="B187" ref-type="bibr">187</xref>). However, a randomized trial including 199 COVID-19 patients showed no immediate <italic>in vivo</italic> benefits of lopinavir/ritonavir (<xref rid="B188" ref-type="bibr">188</xref>). Similarly, clinical trials on chloroquine and hydroxychloroquine have identified methodological limitations and conflicting results, even suggesting a negative effect of hydroxychloroquine (<xref rid="B189" ref-type="bibr">189</xref>&#x02013;<xref rid="B195" ref-type="bibr">195</xref>). In May 2020, a multinational analysis reported the use of hydroxychloroquine or chloroquine, with or without a macrolide, for treatment of COVID-19 comprising data from 671 hospitals in six continents (<xref rid="B196" ref-type="bibr">196</xref>). This study failed to show any beneficial effect of the two drugs; moreover, concerns were raised about whether these drugs caused higher in-hospital mortality (<xref rid="B197" ref-type="bibr">197</xref>). Notably, the study was retracted shortly after publication, whereas the hydroxychloroquine studies currently continue after evaluation of the safety data by the WHO (<xref rid="B198" ref-type="bibr">198</xref>).</p><p>Agents which target the host are also potentially valuable treatment options. Interestingly, the agent camostat mesylate has been reported to block the cellular serine protease TMPRSS2, thereby inhibiting SARS-CoV-2 entry into host cells (<xref rid="B67" ref-type="bibr">67</xref>), and increases survival rates ~60% in an <italic>in vivo</italic> SARS-CoV model (<xref rid="B199" ref-type="bibr">199</xref>). Camostat mesylate is widely used in Japan for chronic pancreatitis and postoperative reflux esophagitis (<xref rid="B200" ref-type="bibr">200</xref>, <xref rid="B201" ref-type="bibr">201</xref>), and currently, a clinical trial in Denmark investigating the impact of this compound on COVID-19 is in its recruitment stage (<xref rid="B202" ref-type="bibr">202</xref>).</p><p>The effectiveness of agents blocking either IL-1 or IL-6, i.e., the receptor-targeted monoclonal antibodies anakinra and tocilizumab, respectively, in the treatment of patients with severe COVID-19 in the ICU have received considerable interest due to the well-established role of these cytokines in immunopathology and association with poor clinical outcome (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Promising results have been reported for individuals or small groups of COVID-19 patients treated with tocilizumab (<xref rid="B203" ref-type="bibr">203</xref>, <xref rid="B204" ref-type="bibr">204</xref>) and anakinra (<xref rid="B205" ref-type="bibr">205</xref>, <xref rid="B206" ref-type="bibr">206</xref>), the latter potentially also beneficial in treating COVID-19 related HLH (<xref rid="B207" ref-type="bibr">207</xref>). The results of ongoing randomized, controlled clinical trials (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B208" ref-type="bibr">208</xref>, <xref rid="B209" ref-type="bibr">209</xref>) will ultimately determine whether such strategies to dampen immune responses will prove beneficial and safe. So far, no significantly increased tendency to severe COVID-19 was reported in patients receiving these medications (DMARDs) for the treatment of rheumatologic conditions (<xref rid="B210" ref-type="bibr">210</xref>). On a more hypothetical basis, the complement system has been suggested as a target for treatment (<xref rid="B211" ref-type="bibr">211</xref>). Finally, numerous ongoing studies are investigating additional novel therapeutic strategies (<xref rid="B212" ref-type="bibr">212</xref>) and candidate vaccines (<xref rid="B213" ref-type="bibr">213</xref>) against SARS-CoV-2. Despite the rapidly evolving number of publications on potential COVID-19 therapeutics, thus far only a very limited number of well-designed clinical trials are available. However, to evaluate the effectiveness and potential adverse effects of future treatments, the results of thorough large-scale, randomized, controlled trials are crucial. Notably, a number of fundamental immunological and virological questions need to be addressed before a vaccine candidate is available. These include aspects related to the mutation rate of the virus, the strength of immunity induced by SARS-CoV-2 and the relative contributions from humoral or cellular immunity, and not least the duration of a protective immune response.</p></sec><sec id="s8"><title>Concluding Remarks</title><p>The current global COVID-19 pandemic is a major challenge for all involved in studies of the role of human genetics in the face of a novel infectious disease. Sequencing children and young or middle-aged individuals with severe COVID-19, who are otherwise healthy, will identify rare, deleterious mutations that lead to SARS-CoV-2 infection and severe clinical outcome. This will offer unique insights on the disease pathogenesis <italic>in natura</italic>, which will undoubtedly offer new therapeutic potentials (<xref rid="B148" ref-type="bibr">148</xref>). Coronaviruses appear at regular intervals, and understanding the molecular mechanisms of COVID-19 development is imperative not only to ending the current pandemic, but also for controlling future potential outbreaks.</p></sec><sec id="s9"><title>Author Contributions</title><p>TM conceived the idea, all authors contributed to the first version of the manuscript. MC-T and TM revised and finalized the manuscript and all co-authors read, corrected, and approved the final version of the manuscript. TM prepared <xref ref-type="fig" rid="F1">Figure 1</xref>, whereas MC-T prepared <xref ref-type="fig" rid="F2">Figure 2</xref> with input from co-authors.</p></sec><sec id="s10"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> The group has received funding for COVID-19 research by Independent Research Council Denmark (0214-00001B) and Grosserer L. F. Foght's foundation.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title>. <source>N Engl J Med.</source> (<year>2020</year>) <volume>382</volume>:<fpage>727</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><?supplied-pmid 31978945?><pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothan</surname><given-names>HA</given-names></name><name><surname>Byrareddy</surname><given-names>SN</given-names></name></person-group>. <article-title>The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak</article-title>. <source>J Autoimmun.</source> (<year>2020</year>) <volume>109</volume>:<fpage>102433</fpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2020.102433</pub-id><?supplied-pmid 32113704?><pub-id pub-id-type="pmid">32113704</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group>. <article-title>Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology</article-title>. <source>Semin Immunopathol.</source> (<year>2017</year>) <volume>39</volume>:<fpage>529</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1007/s00281-017-0629-x</pub-id><?supplied-pmid 28466096?><pub-id pub-id-type="pmid">28466096</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>TS</given-names></name><name><surname>Liu</surname><given-names>DX</given-names></name></person-group>. <article-title>Human coronavirus: host-pathogen interaction</article-title>. <source>Annu Rev Microbiol.</source> (<year>2019</year>) <volume>73</volume>:<fpage>529</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-micro-020518-115759</pub-id><?supplied-pmid 31226023?><pub-id pub-id-type="pmid">31226023</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</article-title>. <source>N Engl J Med.</source> (<year>2020</year>) <volume>382</volume>:<fpage>1199</fpage>&#x02013;<lpage>207</lpage>.<?supplied-pmid 31995857?><pub-id pub-id-type="pmid">31995857</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogensen</surname><given-names>TH</given-names></name></person-group>. <article-title>IRF and STAT transcription factors - from basic biology to roles in infection, protective immunity, and primary immunodeficiencies</article-title>. <source>Front Immunol.</source> (<year>2018</year>) <volume>9</volume>:<fpage>3047</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.03047</pub-id><?supplied-pmid 30671054?><pub-id pub-id-type="pmid">30671054</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousfiha</surname><given-names>A</given-names></name><name><surname>Jeddane</surname><given-names>L</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Ailal</surname><given-names>F</given-names></name><name><surname>Bobby Gaspar</surname><given-names>H</given-names></name><name><surname>Al-Herz</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>The 2017. IUIS phenotypic classification for primary immunodeficiencies</article-title>. <source>J Clin Immunol.</source> (<year>2018</year>) <volume>38</volume>:<fpage>129</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1007/s10875-017-0465-8</pub-id><?supplied-pmid 29226301?><pub-id pub-id-type="pmid">29226301</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name></person-group>. <article-title>Human genetics of infectious diseases: unique insights into immunological redundancy</article-title>. <source>Semin Immunol.</source> (<year>2018</year>) <volume>36</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.smim.2017.12.008</pub-id><?supplied-pmid 29254755?><pub-id pub-id-type="pmid">29254755</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Beziat</surname><given-names>V</given-names></name><name><surname>Mogensen</surname><given-names>TH</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Zhang</surname><given-names>SY</given-names></name></person-group>. <article-title>Human inborn errors of immunity to herpes viruses</article-title>. <source>Curr Opin Immunol.</source> (<year>2020</year>) <volume>62</volume>:<fpage>106</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2020.01.004</pub-id><?supplied-pmid 32014647?><pub-id pub-id-type="pmid">32014647</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name></person-group>. <article-title>The human genetic determinism of life-threatening infectious diseases: genetic heterogeneity and physiological homogeneity?</article-title>
<source>Hum Genet.</source> (<year>2020</year>) <volume>139</volume>:<fpage>681</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-020-02184-w</pub-id><?supplied-pmid 32462426?><pub-id pub-id-type="pmid">32462426</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>SY</given-names></name><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Ugolini</surname><given-names>S</given-names></name><name><surname>Smahi</surname><given-names>A</given-names></name><name><surname>Elain</surname><given-names>G</given-names></name><name><surname>Romero</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>TLR3 deficiency in patients with herpes simplex encephalitis</article-title>. <source>Science.</source> (<year>2007</year>) <volume>317</volume>:<fpage>1522</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1126/science.1139522</pub-id><?supplied-pmid 17872438?><pub-id pub-id-type="pmid">17872438</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>SY</given-names></name><name><surname>Clark</surname><given-names>NE</given-names></name><name><surname>Freije</surname><given-names>CA</given-names></name><name><surname>Pauwels</surname><given-names>E</given-names></name><name><surname>Taggart</surname><given-names>AJ</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Inborn errors of RNA lariat metabolism in humans with brainstem viral infection</article-title>. <source>Cell.</source> (<year>2018</year>) <volume>172</volume>:<fpage>952</fpage>&#x02013;<lpage>65</lpage>.e18. <pub-id pub-id-type="doi">10.1016/j.cell.2018.02.019</pub-id><?supplied-pmid 29474921?><pub-id pub-id-type="pmid">29474921</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogunjimi</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>SY</given-names></name><name><surname>Sorensen</surname><given-names>KB</given-names></name><name><surname>Skipper</surname><given-names>KA</given-names></name><name><surname>Carter-Timofte</surname><given-names>M</given-names></name><name><surname>Kerner</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Inborn errors in RNA polymerase III underlie severe varicella zoster virus infections</article-title>. <source>J Clin Invest.</source> (<year>2017</year>) <volume>127</volume>:<fpage>3543</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1172/JCI92280</pub-id><?supplied-pmid 28783042?><pub-id pub-id-type="pmid">28783042</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter-Timofte</surname><given-names>ME</given-names></name><name><surname>Hansen</surname><given-names>AF</given-names></name><name><surname>Christiansen</surname><given-names>M</given-names></name><name><surname>Paludan</surname><given-names>SR</given-names></name><name><surname>Mogensen</surname><given-names>TH</given-names></name></person-group>. <article-title>Mutations in RNA polymerase III genes and defective DNA sensing in adults with varicella-zoster virus CNS infection</article-title>. <source>Genes Immun</source>. (<year>2019</year>) <volume>20</volume>:<fpage>214</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/s41435-018-0027-y</pub-id><?supplied-pmid 29728610?><pub-id pub-id-type="pmid">29728610</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter-Timofte</surname><given-names>ME</given-names></name><name><surname>Hansen</surname><given-names>AF</given-names></name><name><surname>Mardahl</surname><given-names>M</given-names></name><name><surname>Fribourg</surname><given-names>S</given-names></name><name><surname>Rapaport</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>S-Y</given-names></name><etal/></person-group>. <article-title>Varicella-zoster virus CNS vasculitis and RNA polymerase III gene mutation in identical twins</article-title>. <source>Neurol. Neuroimmunol. Neuroinflamm.</source> (<year>2018</year>) <volume>5</volume>:<fpage>e500</fpage>. <pub-id pub-id-type="doi">10.1212/NXI.0000000000000500</pub-id><?supplied-pmid 30211253?><pub-id pub-id-type="pmid">30211253</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciancanelli</surname><given-names>MJ</given-names></name><name><surname>Huang</surname><given-names>SX</given-names></name><name><surname>Luthra</surname><given-names>P</given-names></name><name><surname>Garner</surname><given-names>H</given-names></name><name><surname>Itan</surname><given-names>Y</given-names></name><name><surname>Volpi</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency</article-title>. <source>Science.</source> (<year>2015</year>) <volume>348</volume>:<fpage>448</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa1578</pub-id><?supplied-pmid 25814066?><pub-id pub-id-type="pmid">25814066</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>N</given-names></name><name><surname>Melki</surname><given-names>I</given-names></name><name><surname>Jing</surname><given-names>H</given-names></name><name><surname>Habib</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>SSY</given-names></name><name><surname>Danielson</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency</article-title>. <source>J Exp Med.</source> (<year>2018</year>) <volume>215</volume>:<fpage>2567</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20180628</pub-id><?supplied-pmid 30143481?><pub-id pub-id-type="pmid">30143481</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>HK</given-names></name><name><surname>Huang</surname><given-names>SXL</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Kerner</surname><given-names>G</given-names></name><name><surname>Gilliaux</surname><given-names>O</given-names></name><name><surname>Bastard</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Severe influenza pneumonitis in children with inherited TLR3 deficiency</article-title>. <source>J Exp Med.</source> (<year>2019</year>) <volume>216</volume>:<fpage>2038</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20181621</pub-id><?supplied-pmid 31217193?><pub-id pub-id-type="pmid">31217193</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sologuren</surname><given-names>I</given-names></name><name><surname>Martinez-Saavedra</surname><given-names>MT</given-names></name><name><surname>Sole-Violan</surname><given-names>J</given-names></name><name><surname>de Borges de Oliveira</surname><given-names>E</given-names><suffix>Jr</suffix></name><name><surname>Betancor</surname><given-names>E</given-names></name><name><surname>Casas</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Lethal influenza in two related adults with inherited GATA2 deficiency</article-title>. <source>J Clin Immunol.</source> (<year>2018</year>) <volume>38</volume>:<fpage>513</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1007/s10875-018-0512-0</pub-id><?supplied-pmid 29882021?><pub-id pub-id-type="pmid">29882021</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>SE</given-names></name><name><surname>Christiansen</surname><given-names>M</given-names></name><name><surname>Ryo</surname><given-names>LB</given-names></name><name><surname>Gad</surname><given-names>HH</given-names></name><name><surname>Gjedsted</surname><given-names>J</given-names></name><name><surname>Staeheli</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Defective RNA sensing by RIG-I in severe influenza virus infection</article-title>. <source>Clin Exp Immunol.</source> (<year>2018</year>) <volume>192</volume>:<fpage>366</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1111/cei.13120</pub-id><?supplied-pmid 29453856?><pub-id pub-id-type="pmid">29453856</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamborn</surname><given-names>IT</given-names></name><name><surname>Jing</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Drutman</surname><given-names>SB</given-names></name><name><surname>Abbott</surname><given-names>JK</given-names></name><name><surname>Munir</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Recurrent rhinovirus infections in a child with inherited MDA5 deficiency</article-title>. <source>J Exp Med.</source> (<year>2017</year>) <volume>214</volume>:<fpage>1949</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20161759</pub-id><?supplied-pmid 28606988?><pub-id pub-id-type="pmid">28606988</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>SJ</given-names></name><name><surname>Crequer</surname><given-names>A</given-names></name><name><surname>Matos</surname><given-names>I</given-names></name><name><surname>Hum</surname><given-names>D</given-names></name><name><surname>Gunasekharan</surname><given-names>V</given-names></name><name><surname>Lorenzo</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>The human CIB1-EVER1-EVER2 complex governs keratinocyte-intrinsic immunity to beta-papillomaviruses</article-title>. <source>J Exp Med.</source> (<year>2018</year>) <volume>215</volume>:<fpage>2289</fpage>&#x02013;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20170308</pub-id><?supplied-pmid 30068544?><pub-id pub-id-type="pmid">30068544</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottino</surname><given-names>C</given-names></name><name><surname>Falco</surname><given-names>M</given-names></name><name><surname>Parolini</surname><given-names>S</given-names></name><name><surname>Marcenaro</surname><given-names>E</given-names></name><name><surname>Augugliaro</surname><given-names>R</given-names></name><name><surname>Sivori</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease</article-title>. <source>J Exp Med.</source> (<year>2001</year>) <volume>194</volume>:<fpage>235</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1084/jem.194.3.235</pub-id><?supplied-pmid 11489943?><pub-id pub-id-type="pmid">11489943</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salzer</surname><given-names>E</given-names></name><name><surname>Daschkey</surname><given-names>S</given-names></name><name><surname>Choo</surname><given-names>S</given-names></name><name><surname>Gombert</surname><given-names>M</given-names></name><name><surname>Santos-Valente</surname><given-names>E</given-names></name><name><surname>Ginzel</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27</article-title>. <source>Haematologica.</source> (<year>2013</year>) <volume>98</volume>:<fpage>473</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3324/haematol.2012.068791</pub-id><?supplied-pmid 22801960?><pub-id pub-id-type="pmid">22801960</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>RA</given-names></name><name><surname>Madden</surname><given-names>L</given-names></name><name><surname>Kitchen</surname><given-names>BJ</given-names></name><name><surname>Mody</surname><given-names>R</given-names></name><name><surname>McClimon</surname><given-names>B</given-names></name><name><surname>Jordan</surname><given-names>MB</given-names></name><etal/></person-group>
<article-title>XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease</article-title>. <source>Blood.</source> (<year>2010</year>) <volume>116</volume>:<fpage>1079</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2010-01-256099</pub-id><pub-id pub-id-type="pmid">20489057</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linka</surname><given-names>RM</given-names></name><name><surname>Risse</surname><given-names>SL</given-names></name><name><surname>Bienemann</surname><given-names>K</given-names></name><name><surname>Werner</surname><given-names>M</given-names></name><name><surname>Linka</surname><given-names>Y</given-names></name><name><surname>Krux</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases</article-title>. <source>Leukemia.</source> (<year>2012</year>) <volume>26</volume>:<fpage>963</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2011.371</pub-id><?supplied-pmid 22289921?><pub-id pub-id-type="pmid">22289921</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>FY</given-names></name><name><surname>Chaigne-Delalande</surname><given-names>B</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Uzel</surname><given-names>G</given-names></name><name><surname>Matthews</surname><given-names>H</given-names></name><name><surname>Lenardo</surname><given-names>MJ</given-names></name></person-group>. <article-title>XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus</article-title>. <source>Blood.</source> (<year>2014</year>) <volume>123</volume>:<fpage>2148</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2013-11-538686</pub-id><?supplied-pmid 24550228?><pub-id pub-id-type="pmid">24550228</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drutman</surname><given-names>SB</given-names></name><name><surname>Mansouri</surname><given-names>D</given-names></name><name><surname>Mahdaviani</surname><given-names>SA</given-names></name><name><surname>Neehus</surname><given-names>AL</given-names></name><name><surname>Hum</surname><given-names>D</given-names></name><name><surname>Bryk</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Fatal cytomegalovirus infection in an adult with inherited NOS2 deficiency</article-title>. <source>N Engl J Med.</source> (<year>2020</year>) <volume>382</volume>:<fpage>437</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1910640</pub-id><?supplied-pmid 31995689?><pub-id pub-id-type="pmid">31995689</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hambleton</surname><given-names>S</given-names></name><name><surname>Goodbourn</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>DF</given-names></name><name><surname>Dickinson</surname><given-names>P</given-names></name><name><surname>Mohamad</surname><given-names>SM</given-names></name><name><surname>Valappil</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>STAT2 deficiency and susceptibility to viral illness in humans</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2013</year>) <volume>110</volume>:<fpage>3053</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1220098110</pub-id><?supplied-pmid 23391734?><pub-id pub-id-type="pmid">23391734</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>CJ</given-names></name><name><surname>Mohamad</surname><given-names>SM</given-names></name><name><surname>Young</surname><given-names>DF</given-names></name><name><surname>Skelton</surname><given-names>AJ</given-names></name><name><surname>Leahy</surname><given-names>TR</given-names></name><name><surname>Munday</surname><given-names>DC</given-names></name><etal/></person-group>. <article-title>Human IFNAR2 deficiency: Lessons for antiviral immunity</article-title>. <source>Sci Transl Med.</source> (<year>2015</year>) <volume>7</volume>:<fpage>307ra154</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aac4227</pub-id><?supplied-pmid 26424569?><pub-id pub-id-type="pmid">26424569</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajema</surname><given-names>KL</given-names></name><name><surname>Oster</surname><given-names>AM</given-names></name><name><surname>McGovern</surname><given-names>OL</given-names></name><name><surname>Lindstrom</surname><given-names>S</given-names></name><name><surname>Stenger</surname><given-names>MR</given-names></name><name><surname>Anderson</surname><given-names>TC</given-names></name><etal/></person-group>. <article-title>Persons evaluated for 2019. novel Coronavirus - United States, January. 2020</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. (<year>2020</year>) <volume>69</volume>:<fpage>166</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm6906e1</pub-id><?supplied-pmid 32053579?><pub-id pub-id-type="pmid">32053579</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>497</fpage>&#x02013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><?supplied-pmid 31986264?><pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Shu</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title>. <source>Lancet Respir Med</source>. (<year>2020</year>) <volume>8</volume>:<fpage>475</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id><?supplied-pmid 32105632?><pub-id pub-id-type="pmid">32105632</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>P</given-names></name><name><surname>Pang</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis</article-title>. <source>J Med Virol</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1002/jmv.25884</pub-id>.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact-tracing study</article-title>. <source>J Infect</source>. (<year>2020</year>) <volume>80</volume>:<fpage>e1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.006</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>McGoogan</surname><given-names>JM</given-names></name></person-group>. <article-title>Characteristics of and important lessons from the coronavirus disease 2019. (COVID-19) outbreak in China: summary of a report of 72314 cases from the chinese center for disease control and prevention</article-title>. <source>JAMA</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id>.<?supplied-pmid 32091533?><pub-id pub-id-type="pmid">32091533</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Clinical characteristics of 138 hospitalized patients with 2019. novel coronavirus-infected pneumonia in Wuhan, China</article-title>. <source>JAMA</source>. (<year>2020</year>) <volume>323</volume>:<fpage>1061</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id><?supplied-pmid 32031570?><pub-id pub-id-type="pmid">32031570</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>WJ</given-names></name><name><surname>Ni</surname><given-names>ZY</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>WH</given-names></name><name><surname>Ou</surname><given-names>CQ</given-names></name><name><surname>He</surname><given-names>JX</given-names></name><etal/></person-group>
<article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>382</volume>:<fpage>1708</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lechien</surname><given-names>JR</given-names></name><name><surname>Chiesa-Estomba</surname><given-names>CM</given-names></name><name><surname>De Siati</surname><given-names>DR</given-names></name><name><surname>Horoi</surname><given-names>M</given-names></name><name><surname>Le Bon</surname><given-names>SD</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study</article-title>. <source>Eur Arch Otorhinolaryngol</source>. (<year>2020</year>) <volume>6</volume>:<fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1007/s00405-020-05965-1</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonardi</surname><given-names>M</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name></person-group>. <article-title>Neurological manifestations associated with COVID-19: a review and a call for action</article-title>. <source>J Neurol</source>. (<year>2020</year>) <volume>267</volume>:<fpage>1573</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-020-09896-z</pub-id><?supplied-pmid 32436101?><pub-id pub-id-type="pmid">32436101</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>GC</given-names></name><name><surname>Spencer</surname><given-names>PS</given-names></name><name><surname>Reis</surname><given-names>J</given-names></name><name><surname>Buguet</surname><given-names>A</given-names></name><name><surname>Faris</surname><given-names>MEA</given-names></name><name><surname>Katrak</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>The neurology of COVID-19 revisited: a proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries</article-title>. <source>J Neurol Sci.</source> (<year>2020</year>) <volume>414</volume>:<fpage>116884</fpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2020.116884</pub-id><?supplied-pmid 32464367?><pub-id pub-id-type="pmid">32464367</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>KS</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Chan</surname><given-names>PP</given-names></name><name><surname>Lung</surname><given-names>KC</given-names></name><name><surname>Tso</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the hong kong cohort and systematic review and meta-analysis</article-title>. <source>Gastroenterology</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1053/j.gastro.2020.03.065</pub-id>.<?supplied-pmid 32251668?><pub-id pub-id-type="pmid">32251668</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>BM</given-names></name></person-group>. <article-title>COVID-19, ECMO, and lymphopenia: a word of caution</article-title>. <source>Lancet Respir Med.</source> (<year>2020</year>) <volume>8</volume>:<fpage>e24</fpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30119-3</pub-id><?supplied-pmid 32178774?><pub-id pub-id-type="pmid">32178774</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connors</surname><given-names>JM</given-names></name><name><surname>Levy</surname><given-names>JH</given-names></name></person-group>. <article-title>COVID-19 and its implications for thrombosis and anticoagulation</article-title>. <source>Blood.</source> (<year>2020</year>) <volume>135</volume>:<fpage>2033</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1182/blood.2020006000</pub-id><?supplied-pmid 32339221?><pub-id pub-id-type="pmid">32339221</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolhnikoff</surname><given-names>M</given-names></name><name><surname>Duarte-Neto</surname><given-names>AN</given-names></name><name><surname>de Almeida Monteiro</surname><given-names>RA</given-names></name><name><surname>da Silva</surname><given-names>LFF</given-names></name><name><surname>de Oliveira</surname><given-names>EP</given-names></name><name><surname>Saldiva</surname><given-names>PHN</given-names></name><etal/></person-group>. <article-title>Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19</article-title>. <source>J Thromb Haemost.</source> (<year>2020</year>) <volume>18</volume>:<fpage>1517</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/jth.14844</pub-id><?supplied-pmid 32294295?><pub-id pub-id-type="pmid">32294295</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Samkari</surname><given-names>H</given-names></name><name><surname>Karp Leaf</surname><given-names>RS</given-names></name><name><surname>Dzik</surname><given-names>WH</given-names></name><name><surname>Carlson</surname><given-names>JC</given-names></name><name><surname>Fogerty</surname><given-names>AE</given-names></name><name><surname>Waheed</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 Infection</article-title>. <source>Blood</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1182/blood.2020006520</pub-id>.<?supplied-pmid 32492712?><pub-id pub-id-type="pmid">32492712</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edler</surname><given-names>C</given-names></name><name><surname>Schroder</surname><given-names>AS</given-names></name><name><surname>Aepfelbacher</surname><given-names>M</given-names></name><name><surname>Fitzek</surname><given-names>A</given-names></name><name><surname>Heinemann</surname><given-names>A</given-names></name><name><surname>Heinrich</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany</article-title>. <source>Int J Legal Med</source>. (<year>2020</year>) <volume>134</volume>:<fpage>1275</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1007/s00414-020-02317-w</pub-id><?supplied-pmid 32500199?><pub-id pub-id-type="pmid">32500199</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagunas-Rangel</surname><given-names>FA</given-names></name><name><surname>Chavez-Valencia</surname><given-names>V</given-names></name></person-group>. <article-title>High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients</article-title>. <source>J Med Virol</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1002/jmv.25900</pub-id>.<?supplied-pmid 32297995?><pub-id pub-id-type="pmid">32297995</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>LA</given-names></name><name><surname>Canna</surname><given-names>SW</given-names></name><name><surname>Schulert</surname><given-names>GS</given-names></name><name><surname>Volpi</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>PY</given-names></name><name><surname>Kernan</surname><given-names>KF</given-names></name><etal/></person-group>. <article-title>On the alert for cytokine storm: immunopathology in COVID-19</article-title>. <source>Arthritis Rheumatol</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1002/art.41285</pub-id>.<?supplied-pmid 32293098?><pub-id pub-id-type="pmid">32293098</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>X</given-names></name></person-group>. <article-title>COVID-19: immunopathology and its implications for therapy</article-title>. <source>Nat Rev Immunol</source>. (<year>2020</year>) <volume>20</volume>:<fpage>269</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-0308-3</pub-id><?supplied-pmid 32273594?><pub-id pub-id-type="pmid">32273594</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Licciardi</surname><given-names>F</given-names></name><name><surname>Giani</surname><given-names>T</given-names></name><name><surname>Baldini</surname><given-names>L</given-names></name><name><surname>Favalli</surname><given-names>EG</given-names></name><name><surname>Caporali</surname><given-names>R</given-names></name><name><surname>Cimaz</surname><given-names>R</given-names></name></person-group>. <article-title>COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country</article-title>. <source>Pediatr Rheumatol Online J.</source> (<year>2020</year>) <volume>18</volume>:<fpage>35</fpage>. <pub-id pub-id-type="doi">10.1186/s12969-020-00422-z</pub-id><?supplied-pmid 32321540?><pub-id pub-id-type="pmid">32321540</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>AI</given-names></name><name><surname>Singanayagam</surname><given-names>A</given-names></name></person-group>. <article-title>Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?</article-title>
<source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>1111</fpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30691-7</pub-id><?supplied-pmid 32220278?><pub-id pub-id-type="pmid">32220278</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>VG</given-names></name><name><surname>Mills</surname><given-names>M</given-names></name><name><surname>Suarez</surname><given-names>D</given-names></name><name><surname>Hogan</surname><given-names>CA</given-names></name><name><surname>Yeh</surname><given-names>D</given-names></name><name><surname>Bradley Segal</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>COVID-19 and kawasaki disease: novel virus and novel case</article-title>. <source>Hosp Pediatr</source>. (<year>2020</year>) <volume>10</volume>:<fpage>537</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1542/hpeds.2020-0123</pub-id><?supplied-pmid 32265235?><pub-id pub-id-type="pmid">32265235</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riphagen</surname><given-names>S</given-names></name><name><surname>Gomez</surname><given-names>X</given-names></name><name><surname>Gonzalez-Martinez</surname><given-names>C</given-names></name><name><surname>Wilkinson</surname><given-names>N</given-names></name><name><surname>Theocharis</surname><given-names>P</given-names></name></person-group>. <article-title>Hyperinflammatory shock in children during COVID-19 pandemic</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>1607</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31094-1</pub-id><?supplied-pmid 32386565?><pub-id pub-id-type="pmid">32386565</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>PC</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lau</surname><given-names>SK</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group>. <article-title>Coronavirus genomics and bioinformatics analysis</article-title>. <source>Viruses.</source> (<year>2010</year>) <volume>2</volume>:<fpage>1804</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.3390/v2081803</pub-id><?supplied-pmid 21994708?><pub-id pub-id-type="pmid">21994708</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>PC</given-names></name><name><surname>Lau</surname><given-names>SK</given-names></name><name><surname>Lam</surname><given-names>CS</given-names></name><name><surname>Lau</surname><given-names>CC</given-names></name><name><surname>Tsang</surname><given-names>AK</given-names></name><name><surname>Lau</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus</article-title>. <source>J Virol.</source> (<year>2012</year>) <volume>86</volume>:<fpage>3995</fpage>&#x02013;<lpage>4008</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.06540-11</pub-id><?supplied-pmid 22278237?><pub-id pub-id-type="pmid">22278237</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>565</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id><?supplied-pmid 32007145?><pub-id pub-id-type="pmid">32007145</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>XG</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature.</source> (<year>2020</year>) <volume>579</volume>:<fpage>270</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><?supplied-pmid 32015507?><pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zai</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Nie</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Foley</surname><given-names>BT</given-names></name><etal/></person-group>. <article-title>Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2</article-title>. <source>J Med Virol</source>. (<year>2020</year>) <volume>92</volume>:<fpage>602</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25731</pub-id><?supplied-pmid 32104911?><pub-id pub-id-type="pmid">32104911</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>KG</given-names></name><name><surname>Rambaut</surname><given-names>A</given-names></name><name><surname>Lipkin</surname><given-names>WI</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name><name><surname>Garry</surname><given-names>RF</given-names></name></person-group>. <article-title>The proximal origin of SARS-CoV-2</article-title>. <source>Nat Med.</source> (<year>2020</year>) <volume>26</volume>:<fpage>450</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0820-9</pub-id><?supplied-pmid 32284615?><pub-id pub-id-type="pmid">32284615</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</article-title>. <source>Acta Pharm Sin B</source>. (<year>2020</year>) <volume>92</volume>:<fpage>602</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2020.02.008</pub-id><?supplied-pmid 32292689?><pub-id pub-id-type="pmid">32292689</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Vasilieva</surname><given-names>N</given-names></name><name><surname>Sui</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>SK</given-names></name><name><surname>Berne</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title>. <source>Nature.</source> (<year>2003</year>) <volume>426</volume>:<fpage>450</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/nature02145</pub-id><?supplied-pmid 14647384?><pub-id pub-id-type="pmid">14647384</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S</given-names></name><name><surname>Nagata</surname><given-names>N</given-names></name><name><surname>Shirato</surname><given-names>K</given-names></name><name><surname>Kawase</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Taguchi</surname><given-names>F</given-names></name></person-group>. <article-title>Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2</article-title>. <source>J Virol.</source> (<year>2010</year>) <volume>84</volume>:<fpage>12658</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01542-10</pub-id><?supplied-pmid 20926566?><pub-id pub-id-type="pmid">20926566</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shulla</surname><given-names>A</given-names></name><name><surname>Heald-Sargent</surname><given-names>T</given-names></name><name><surname>Subramanya</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name><name><surname>Gallagher</surname><given-names>T</given-names></name></person-group>. <article-title>A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry</article-title>. <source>J Virol.</source> (<year>2011</year>) <volume>85</volume>:<fpage>873</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02062-10</pub-id><?supplied-pmid 21068237?><pub-id pub-id-type="pmid">21068237</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XH</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>YX</given-names></name><name><surname>Zhang</surname><given-names>LF</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection</article-title>. <source>Comp Med.</source> (<year>2007</year>) <volume>57</volume>:<fpage>450</fpage>&#x02013;<lpage>9</lpage>.<?supplied-pmid 17974127?><pub-id pub-id-type="pmid">17974127</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Goldsmith</surname><given-names>JA</given-names></name><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Abiona</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title>. <source>Science.</source> (<year>2020</year>) <volume>367</volume>:<fpage>1260</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><?supplied-pmid 32075877?><pub-id pub-id-type="pmid">32075877</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kruger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>181</volume>:<fpage>271</fpage>&#x02013;<lpage>80</lpage>.e8. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><?supplied-pmid 32142651?><pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Shan</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title>. <source>Nature</source>. (<year>2020</year>) <volume>581</volume>:<fpage>215</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2180-5</pub-id><?supplied-pmid 32225176?><pub-id pub-id-type="pmid">32225176</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchdoerfer</surname><given-names>RN</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Pallesen</surname><given-names>J</given-names></name><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Turner</surname><given-names>HL</given-names></name><name><surname>Cottrell</surname><given-names>CA</given-names></name><etal/></person-group>
<article-title>Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis</article-title>. <source>Sci Rep.</source> (<year>2018</year>) <volume>8</volume>:<fpage>15701</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-36918-8</pub-id><pub-id pub-id-type="pmid">30356097</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Zuo</surname><given-names>W</given-names></name></person-group>
<article-title>Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov</article-title>. <source>bioRxiv.</source> (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1101/2020.01.26.919985</pub-id>.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I</given-names></name><name><surname>Timens</surname><given-names>W</given-names></name><name><surname>Bulthuis</surname><given-names>ML</given-names></name><name><surname>Lely</surname><given-names>AT</given-names></name><name><surname>Navis</surname><given-names>G</given-names></name><name><surname>van Goor</surname><given-names>H</given-names></name></person-group>. <article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. a first step in understanding SARS pathogenesis</article-title>. <source>J Pathol.</source> (<year>2004</year>) <volume>203</volume>:<fpage>631</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/path.1570</pub-id><?supplied-pmid 15141377?><pub-id pub-id-type="pmid">15141377</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>P</given-names></name><name><surname>Hao</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name></person-group>. <article-title>Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection</article-title>. <source>Front Med</source>. (<year>2020</year>) <volume>14</volume>:<fpage>185</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1007/s11684-020-0754-0</pub-id><?supplied-pmid 32170560?><pub-id pub-id-type="pmid">32170560</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Clinical and immunologic features in severe and moderate Coronavirus Disease 2019</article-title>. <source>J Clin Invest</source>. (<year>2020</year>) <volume>130</volume>:<fpage>2620</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1101/2020.02.16.20023903</pub-id><?supplied-pmid 32217835?><pub-id pub-id-type="pmid">32217835</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prompetchara</surname><given-names>E</given-names></name><name><surname>Ketloy</surname><given-names>C</given-names></name><name><surname>Palaga</surname><given-names>T</given-names></name></person-group>. <article-title>Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic</article-title>. <source>Asian Pac J Allergy Immunol.</source> (<year>2020</year>) <volume>38</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.12932/AP-200220-0772</pub-id><?supplied-pmid 32105090?><pub-id pub-id-type="pmid">32105090</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name></person-group>. <article-title>Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response</article-title>. <source>Microbes Infect.</source> (<year>2013</year>) <volume>15</volume>:<fpage>88</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2012.10.008</pub-id><?supplied-pmid 23123977?><pub-id pub-id-type="pmid">23123977</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>T</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name></person-group>. <article-title>Toll-like receptor signaling pathways</article-title>. <source>Front Immunol.</source> (<year>2014</year>) <volume>5</volume>:<fpage>461</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00461</pub-id><?supplied-pmid 25309543?><pub-id pub-id-type="pmid">25309543</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totura</surname><given-names>AL</given-names></name><name><surname>Whitmore</surname><given-names>A</given-names></name><name><surname>Agnihothram</surname><given-names>S</given-names></name><name><surname>Schafer</surname><given-names>A</given-names></name><name><surname>Katze</surname><given-names>MG</given-names></name><name><surname>Heise</surname><given-names>MT</given-names></name><etal/></person-group>. <article-title>Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection</article-title>. <source>mBio.</source> (<year>2015</year>) <volume>6</volume>:<fpage>e00638</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.00638-15</pub-id><?supplied-pmid 26015500?><pub-id pub-id-type="pmid">26015500</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T</given-names></name><name><surname>Morrison</surname><given-names>TE</given-names></name><name><surname>Funkhouser</surname><given-names>W</given-names></name><name><surname>Uematsu</surname><given-names>S</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV</article-title>. <source>PLoS Pathog.</source> (<year>2008</year>) <volume>4</volume>:<fpage>e1000240</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1000240</pub-id><?supplied-pmid 19079579?><pub-id pub-id-type="pmid">19079579</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Menachery</surname><given-names>VD</given-names></name><name><surname>Morgan</surname><given-names>AP</given-names></name><name><surname>Totura</surname><given-names>AL</given-names></name><name><surname>Beall</surname><given-names>A</given-names></name><name><surname>Kocher</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Allelic variation in the toll-like receptor adaptor protein <italic>Ticam2</italic> contributes to SARS-coronavirus pathogenesis in mice</article-title>. <source>G3.</source> (<year>2017</year>) <volume>7</volume>:<fpage>1653</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1534/g3.117.041434</pub-id><?supplied-pmid 28592648?><pub-id pub-id-type="pmid">28592648</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>MJ</given-names></name><name><surname>Ran</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Danesh</surname><given-names>A</given-names></name><name><surname>Bermejo-Martin</surname><given-names>JF</given-names></name><name><surname>Cameron</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome</article-title>. <source>J Virol.</source> (<year>2007</year>) <volume>81</volume>:<fpage>8692</fpage>&#x02013;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00527-07</pub-id><?supplied-pmid 17537853?><pub-id pub-id-type="pmid">17537853</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faure</surname><given-names>E</given-names></name><name><surname>Poissy</surname><given-names>J</given-names></name><name><surname>Goffard</surname><given-names>A</given-names></name><name><surname>Fournier</surname><given-names>C</given-names></name><name><surname>Kipnis</surname><given-names>E</given-names></name><name><surname>Titecat</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?</article-title>
<source>PLoS One.</source> (<year>2014</year>) <volume>9</volume>:<fpage>e88716</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0088716</pub-id><?supplied-pmid 24551142?><pub-id pub-id-type="pmid">24551142</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ku</surname><given-names>CL</given-names></name><name><surname>von Bernuth</surname><given-names>H</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>SY</given-names></name><name><surname>Chang</surname><given-names>HH</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity</article-title>. <source>J Exp Med.</source> (<year>2007</year>) <volume>204</volume>:<fpage>2407</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20070628</pub-id><?supplied-pmid 17893200?><pub-id pub-id-type="pmid">17893200</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name></person-group>. <article-title>Lethal infectious diseases as inborn errors of immunity: toward a synthesis of the germ and genetic theories</article-title>. <source>Annu Rev Pathol</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1146/annurev-pathol-031920-101429</pub-id>.<?supplied-pmid 32289233?><pub-id pub-id-type="pmid">32289233</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zalinger</surname><given-names>ZB</given-names></name><name><surname>Elliott</surname><given-names>R</given-names></name><name><surname>Rose</surname><given-names>KM</given-names></name><name><surname>Weiss</surname><given-names>SR</given-names></name></person-group>. <article-title>MDA5 Is Critical to Host Defense during Infection with Murine Coronavirus</article-title>. <source>J Virol.</source> (<year>2015</year>) <volume>89</volume>:<fpage>12330</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01470-15</pub-id><?supplied-pmid 26423942?><pub-id pub-id-type="pmid">26423942</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menachery</surname><given-names>VD</given-names></name><name><surname>Debbink</surname><given-names>K</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group>. <article-title>Coronavirus non-structural protein 16: evasion, attenuation, and possible treatments</article-title>. <source>Virus Res.</source> (<year>2014</year>) <volume>194</volume>:<fpage>191</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2014.09.009</pub-id><?supplied-pmid 25278144?><pub-id pub-id-type="pmid">25278144</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menachery</surname><given-names>VD</given-names></name><name><surname>Yount</surname><given-names>BL</given-names><suffix>Jr.</suffix></name><name><surname>Josset</surname><given-names>L</given-names></name><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Scobey</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2'-o-methyltransferase activity</article-title>. <source>J Virol.</source> (<year>2014</year>) <volume>88</volume>:<fpage>4251</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.03571-13</pub-id><?supplied-pmid 24478444?><pub-id pub-id-type="pmid">24478444</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zust</surname><given-names>R</given-names></name><name><surname>Cervantes-Barragan</surname><given-names>L</given-names></name><name><surname>Habjan</surname><given-names>M</given-names></name><name><surname>Maier</surname><given-names>R</given-names></name><name><surname>Neuman</surname><given-names>BW</given-names></name><name><surname>Ziebuhr</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5</article-title>. <source>Nat Immunol.</source> (<year>2011</year>) <volume>12</volume>:<fpage>137</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1979</pub-id><?supplied-pmid 21217758?><pub-id pub-id-type="pmid">21217758</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>PS</given-names></name><name><surname>Molony</surname><given-names>RD</given-names></name><name><surname>Martinod</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Pang</surname><given-names>IK</given-names></name><name><surname>Tal</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease</article-title>. <source>Science.</source> (<year>2016</year>) <volume>352</volume>:<fpage>463</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaf3926</pub-id><?supplied-pmid 27102485?><pub-id pub-id-type="pmid">27102485</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto-Torres</surname><given-names>JL</given-names></name><name><surname>Verdia-Baguena</surname><given-names>C</given-names></name><name><surname>Jimenez-Guardeno</surname><given-names>JM</given-names></name><name><surname>Regla-Nava</surname><given-names>JA</given-names></name><name><surname>Castano-Rodriguez</surname><given-names>C</given-names></name><name><surname>Fernandez-Delgado</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome</article-title>. <source>Virology.</source> (<year>2015</year>) <volume>485</volume>:<fpage>330</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2015.08.010</pub-id><?supplied-pmid 26331680?><pub-id pub-id-type="pmid">26331680</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>CS</given-names></name><name><surname>Nabar</surname><given-names>NR</given-names></name><name><surname>Huang</surname><given-names>NN</given-names></name><name><surname>Kehrl</surname><given-names>JH</given-names></name></person-group>. <article-title>SARS-Coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes</article-title>. <source>Cell Death Discov.</source> (<year>2019</year>) <volume>5</volume>:<fpage>101</fpage>. <pub-id pub-id-type="doi">10.1038/s41420-019-0181-7</pub-id><?supplied-pmid 31231549?><pub-id pub-id-type="pmid">31231549</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>IY</given-names></name><name><surname>Moriyama</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>MF</given-names></name><name><surname>Ichinohe</surname><given-names>T</given-names></name></person-group>. <article-title>Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome</article-title>. <source>Front Microbiol.</source> (<year>2019</year>) <volume>10</volume>:<fpage>50</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2019.00050</pub-id><?supplied-pmid 30761102?><pub-id pub-id-type="pmid">30761102</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>JKY</given-names></name><name><surname>Moriyama</surname><given-names>M</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group>. <article-title>Inflammasomes and pyroptosis as therapeutic targets for COVID-19</article-title>. <source>J Immunol</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.4049/jimmunol.2000513</pub-id>.<?supplied-pmid 32493814?><pub-id pub-id-type="pmid">32493814</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>BJ</given-names></name><name><surname>Adrover</surname><given-names>JM</given-names></name><name><surname>Baxter-Stoltzfus</surname><given-names>A</given-names></name><name><surname>Borczuk</surname><given-names>A</given-names></name><name><surname>Cools-Lartigue</surname><given-names>J</given-names></name><name><surname>Crawford</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Targeting potential drivers of COVID-19: Neutrophil extracellular traps</article-title>. <source>J Exp Med.</source> (<year>2020</year>) <volume>217</volume>:<fpage>e20200652</fpage>. <pub-id pub-id-type="doi">10.1084/jem.20200652</pub-id><?supplied-pmid 32302401?><pub-id pub-id-type="pmid">32302401</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>Y</given-names></name><name><surname>Yalavarthi</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Gockman</surname><given-names>K</given-names></name><name><surname>Zuo</surname><given-names>M</given-names></name><name><surname>Madison</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Neutrophil extracellular traps in COVID-19</article-title>. <source>JCI Insight.</source> (<year>2020</year>) <volume>5</volume>:<fpage>11</fpage>. <pub-id pub-id-type="doi">10.1101/2020.04.30.20086736</pub-id><?supplied-pmid 32329756?><pub-id pub-id-type="pmid">32329756</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>H</given-names></name><name><surname>Linde</surname><given-names>A</given-names></name><name><surname>Strannegard</surname><given-names>O</given-names></name></person-group>. <article-title>In vitro inhibition of SARS virus replication by human interferons</article-title>. <source>Scand J Infect Dis.</source> (<year>2004</year>) <volume>36</volume>:<fpage>829</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1080/00365540410021144</pub-id><?supplied-pmid 15764169?><pub-id pub-id-type="pmid">15764169</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haagmans</surname><given-names>BL</given-names></name><name><surname>Kuiken</surname><given-names>T</given-names></name><name><surname>Martina</surname><given-names>BE</given-names></name><name><surname>Fouchier</surname><given-names>RA</given-names></name><name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name><name><surname>van Amerongen</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques</article-title>. <source>Nat Med.</source> (<year>2004</year>) <volume>10</volume>:<fpage>290</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/nm1001</pub-id><?supplied-pmid 14981511?><pub-id pub-id-type="pmid">14981511</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sainz</surname><given-names>B</given-names><suffix>Jr.</suffix></name><name><surname>Mossel</surname><given-names>EC</given-names></name><name><surname>Peters</surname><given-names>CJ</given-names></name><name><surname>Garry</surname><given-names>RF</given-names></name></person-group>. <article-title>Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)</article-title>. <source>Virology.</source> (<year>2004</year>) <volume>329</volume>:<fpage>11</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2004.08.011</pub-id><?supplied-pmid 15476870?><pub-id pub-id-type="pmid">15476870</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stroher</surname><given-names>U</given-names></name><name><surname>DiCaro</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Strong</surname><given-names>JE</given-names></name><name><surname>Aoki</surname><given-names>F</given-names></name><name><surname>Plummer</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha</article-title>. <source>J Infect Dis.</source> (<year>2004</year>) <volume>189</volume>:<fpage>1164</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1086/382597</pub-id><?supplied-pmid 15031783?><pub-id pub-id-type="pmid">15031783</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumaki</surname><given-names>Y</given-names></name><name><surname>Ennis</surname><given-names>J</given-names></name><name><surname>Rahbar</surname><given-names>R</given-names></name><name><surname>Turner</surname><given-names>JD</given-names></name><name><surname>Wandersee</surname><given-names>MK</given-names></name><name><surname>Smith</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model</article-title>. <source>Antiviral Res.</source> (<year>2011</year>) <volume>89</volume>:<fpage>75</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2010.11.007</pub-id><?supplied-pmid 21093489?><pub-id pub-id-type="pmid">21093489</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>Morgenstern</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>G</given-names></name><name><surname>Chandra</surname><given-names>P</given-names></name><name><surname>Rabenau</surname><given-names>H</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name></person-group>. <article-title>Treatment of SARS with human interferons</article-title>. <source>Lancet.</source> (<year>2003</year>) <volume>362</volume>:<fpage>293</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)13973-6</pub-id><?supplied-pmid 12892961?><pub-id pub-id-type="pmid">12892961</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totura</surname><given-names>AL</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group>. <article-title>SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon</article-title>. <source>Curr Opin Virol.</source> (<year>2012</year>) <volume>2</volume>:<fpage>264</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2012.04.004</pub-id><?supplied-pmid 22572391?><pub-id pub-id-type="pmid">22572391</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Hill</surname><given-names>TE</given-names></name><name><surname>Yoshikawa</surname><given-names>N</given-names></name><name><surname>Popov</surname><given-names>VL</given-names></name><name><surname>Galindo</surname><given-names>CL</given-names></name><name><surname>Garner</surname><given-names>HR</given-names></name><etal/></person-group>. <article-title>Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection</article-title>. <source>PLoS One.</source> (<year>2010</year>) <volume>5</volume>:<fpage>e8729</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0008729</pub-id><?supplied-pmid 20090954?><pub-id pub-id-type="pmid">20090954</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco-Melo</surname><given-names>D</given-names></name><name><surname>Nilsson-Payant</surname><given-names>BE</given-names></name><name><surname>Liu</surname><given-names>WC</given-names></name><name><surname>Uhl</surname><given-names>S</given-names></name><name><surname>Hoagland</surname><given-names>D</given-names></name><name><surname>Moller</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Imbalanced host response to SARS-CoV-2 drives development of COVID-19</article-title>. <source>Cell.</source> (<year>2020</year>) <volume>181</volume>:<fpage>1036</fpage>&#x02013;<lpage>45. e9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.04.026</pub-id><?supplied-pmid 32416070?><pub-id pub-id-type="pmid">32416070</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>JF</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yuen</surname><given-names>TT</given-names></name><name><surname>Chai</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an <italic>ex vivo</italic> study with implications for the pathogenesis of COVID-19</article-title>. <source>Clin Infect Dis</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1093/cid/ciaa410</pub-id>.<?supplied-pmid 32270184?><pub-id pub-id-type="pmid">32270184</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindler</surname><given-names>E</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name></person-group>. <article-title>To sense or not to sense viral RNA&#x02013;essentials of coronavirus innate immune evasion</article-title>. <source>Curr Opin Microbiol.</source> (<year>2014</year>) <volume>20</volume>:<fpage>69</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.mib.2014.05.005</pub-id><?supplied-pmid 24908561?><pub-id pub-id-type="pmid">24908561</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinzula</surname><given-names>L</given-names></name><name><surname>Tramontano</surname><given-names>E</given-names></name></person-group>. <article-title>Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: hide, mask, hit</article-title>. <source>Antiviral Res.</source> (<year>2013</year>) <volume>100</volume>:<fpage>615</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.10.002</pub-id><?supplied-pmid 24129118?><pub-id pub-id-type="pmid">24129118</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindler</surname><given-names>E</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name><name><surname>Weber</surname><given-names>F</given-names></name></person-group>. <article-title>Interaction of SARS and MERS coronaviruses with the antiviral interferon response</article-title>. <source>Adv Virus Res.</source> (<year>2016</year>) <volume>96</volume>:<fpage>219</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/bs.aivir.2016.08.006</pub-id><?supplied-pmid 27712625?><pub-id pub-id-type="pmid">27712625</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group>. <article-title>T cell-mediated immune response to respiratory coronaviruses</article-title>. <source>Immunol Res.</source> (<year>2014</year>) <volume>59</volume>:<fpage>118</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1007/s12026-014-8534-z</pub-id><?supplied-pmid 24845462?><pub-id pub-id-type="pmid">24845462</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CK</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>T cell responses to whole SARS coronavirus in humans</article-title>. <source>J Immunol.</source> (<year>2008</year>) <volume>181</volume>:<fpage>5490</fpage>&#x02013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.181.8.5490</pub-id><?supplied-pmid 18832706?><pub-id pub-id-type="pmid">18832706</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Dysregulation of immune response in patients with COVID-19 in Wuhan, China</article-title>. <source>Clin Infect Dis</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1093/cid/ciaa248</pub-id>.<?supplied-pmid 32161940?><pub-id pub-id-type="pmid">32161940</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>SF</given-names></name><name><surname>Ho</surname><given-names>YC</given-names></name></person-group>. <article-title>SARS-CoV-2: a storm is raging</article-title>. <source>J Clin Invest</source>. (<year>2020</year>) <volume>130</volume>:<fpage>2202</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1172/JCI137647</pub-id><?supplied-pmid 32217834?><pub-id pub-id-type="pmid">32217834</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ning</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019</article-title>. (COVID-19). <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<fpage>827</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.00827</pub-id><?supplied-pmid 32425950?><pub-id pub-id-type="pmid">32425950</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>HY</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>CX</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>XC</given-names></name><name><surname>Yang</surname><given-names>XP</given-names></name><etal/></person-group>. <article-title>Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients</article-title>. <source>Cell Mol Immunol</source>. (<year>2020</year>) <volume>17</volume>:<fpage>541</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-020-0401-3</pub-id><?supplied-pmid 32203186?><pub-id pub-id-type="pmid">32203186</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Moderbacher</surname><given-names>CR</given-names></name><etal/></person-group>. <article-title>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title>. <source>Cell</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id>.<?supplied-pmid 32473127?><pub-id pub-id-type="pmid">32473127</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Fett</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group>. <article-title>Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection</article-title>. <source>J Virol.</source> (<year>2014</year>) <volume>88</volume>:<fpage>11034</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01505-14</pub-id><?supplied-pmid 25056892?><pub-id pub-id-type="pmid">25056892</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title>. <source>Lancet Respir Med.</source> (<year>2020</year>) <volume>8</volume>:<fpage>420</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30076-X</pub-id><?supplied-pmid 32085846?><pub-id pub-id-type="pmid">32085846</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title>. <source>Nat Med</source>. (<year>2020</year>) <volume>26</volume>:<fpage>842</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0901-9</pub-id><?supplied-pmid 32398875?><pub-id pub-id-type="pmid">32398875</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name><name><surname>Vijay</surname><given-names>R</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><etal/></person-group>. <article-title>Dysregulated type i interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected Mice</article-title>. <source>Cell Host Microbe.</source> (<year>2016</year>) <volume>19</volume>:<fpage>181</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.01.007</pub-id><?supplied-pmid 26867177?><pub-id pub-id-type="pmid">26867177</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfel</surname><given-names>R</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Guggemos</surname><given-names>W</given-names></name><name><surname>Seilmaier</surname><given-names>M</given-names></name><name><surname>Zange</surname><given-names>S</given-names></name><name><surname>Muller</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Virological assessment of hospitalized patients with COVID-2019</article-title>. <source>Nature</source>. (<year>2020</year>) <volume>581</volume>:<fpage>465</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2196-x</pub-id><?supplied-pmid 32235945?><pub-id pub-id-type="pmid">32235945</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsueh</surname><given-names>PR</given-names></name><name><surname>Huang</surname><given-names>LM</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Kao</surname><given-names>CL</given-names></name><name><surname>Yang</surname><given-names>PC</given-names></name></person-group>. <article-title>Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus</article-title>. <source>Clin Microbiol Infect.</source> (<year>2004</year>) <volume>10</volume>:<fpage>1062</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-0691.2004.01009.x</pub-id><?supplied-pmid 15606632?><pub-id pub-id-type="pmid">15606632</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M</given-names></name></person-group>. <article-title>SARS Immunity and Vaccination</article-title>. <source>Cell Mol Immunol.</source> (<year>2004</year>) <volume>1</volume>:<fpage>193</fpage>&#x02013;<lpage>8</lpage>.<?supplied-pmid 16219167?><pub-id pub-id-type="pmid">16219167</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name></person-group>. <article-title>Profile of specific antibodies to the SARS-associated coronavirus</article-title>. <source>N Engl J Med.</source> (<year>2003</year>) <volume>349</volume>:<fpage>508</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM200307313490520</pub-id><?supplied-pmid 12890855?><pub-id pub-id-type="pmid">12890855</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellam</surname><given-names>P</given-names></name><name><surname>Barclay</surname><given-names>W</given-names></name></person-group>. <article-title>The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection</article-title>. <source>J Gen Virol</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1099/jgv.0.001439</pub-id>.<?supplied-pmid 32430094?><pub-id pub-id-type="pmid">32430094</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>QX</given-names></name><name><surname>Liu</surname><given-names>BZ</given-names></name><name><surname>Deng</surname><given-names>HJ</given-names></name><name><surname>Wu</surname><given-names>GC</given-names></name><name><surname>Deng</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>YK</given-names></name><etal/></person-group>. <article-title>Antibody responses to SARS-CoV-2 in patients with COVID-19</article-title>. <source>Nat Med</source>. (<year>2020</year>) <volume>26</volume>:<fpage>845</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0897-1</pub-id><?supplied-pmid 32350462?><pub-id pub-id-type="pmid">32350462</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Liao</surname><given-names>X</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019</article-title>. <source>Clin Infect Dis</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1093/cid/ciaa344</pub-id>.</mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>To</surname><given-names>KK</given-names></name><name><surname>Tsang</surname><given-names>OT</given-names></name><name><surname>Leung</surname><given-names>WS</given-names></name><name><surname>Tam</surname><given-names>AR</given-names></name><name><surname>Wu</surname><given-names>TC</given-names></name><name><surname>Lung</surname><given-names>DC</given-names></name><etal/></person-group>. <article-title>Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study</article-title>. <source>Lancet Infect Dis</source>. (<year>2020</year>) <volume>20</volume>:<fpage>565</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30196-1</pub-id><?supplied-pmid 32213337?><pub-id pub-id-type="pmid">32213337</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Fontanet</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>PH</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Xin</surname><given-names>ZT</given-names></name><name><surname>Baril</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome</article-title>. <source>J Infect Dis.</source> (<year>2006</year>) <volume>193</volume>:<fpage>792</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1086/500469</pub-id><?supplied-pmid 16479513?><pub-id pub-id-type="pmid">16479513</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>LP</given-names></name><name><surname>Wang</surname><given-names>NC</given-names></name><name><surname>Chang</surname><given-names>YH</given-names></name><name><surname>Tian</surname><given-names>XY</given-names></name><name><surname>Na</surname><given-names>DY</given-names></name><name><surname>Zhang</surname><given-names>LY</given-names></name><etal/></person-group>. <article-title>Duration of antibody responses after severe acute respiratory syndrome</article-title>. <source>Emerg Infect Dis.</source> (<year>2007</year>) <volume>13</volume>:<fpage>1562</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.3201/eid1310.070576</pub-id><?supplied-pmid 18258008?><pub-id pub-id-type="pmid">18258008</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>OW</given-names></name><name><surname>Chia</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Jadi</surname><given-names>RS</given-names></name><name><surname>Leong</surname><given-names>HN</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection</article-title>. <source>Vaccine.</source> (<year>2016</year>) <volume>34</volume>:<fpage>2008</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.063</pub-id><?supplied-pmid 26954467?><pub-id pub-id-type="pmid">26954467</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longdon</surname><given-names>B</given-names></name><name><surname>Brockhurst</surname><given-names>MA</given-names></name><name><surname>Russell</surname><given-names>CA</given-names></name><name><surname>Welch</surname><given-names>JJ</given-names></name><name><surname>Jiggins</surname><given-names>FM</given-names></name></person-group>. <article-title>The evolution and genetics of virus host shifts</article-title>. <source>PLoS Pathog.</source> (<year>2014</year>) <volume>10</volume>:<fpage>e1004395</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1004395</pub-id><?supplied-pmid 25375777?><pub-id pub-id-type="pmid">25375777</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucciol</surname><given-names>G</given-names></name><name><surname>Moens</surname><given-names>L</given-names></name><name><surname>Bosch</surname><given-names>B</given-names></name><name><surname>Bossuyt</surname><given-names>X</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Puel</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Lessons learned from the study of human inborn errors of innate immunity</article-title>. <source>J Allergy Clin Immunol.</source> (<year>2019</year>) <volume>143</volume>:<fpage>507</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2018.07.013</pub-id><?supplied-pmid 30075154?><pub-id pub-id-type="pmid">30075154</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>T</given-names></name><name><surname>Matikainen</surname><given-names>S</given-names></name><name><surname>Ronkko</surname><given-names>E</given-names></name><name><surname>Osterlund</surname><given-names>P</given-names></name><name><surname>Sillanpaa</surname><given-names>M</given-names></name><name><surname>Siren</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Severe acute respiratory syndrome coronavirus fails to activate cytokine-mediated innate immune responses in cultured human monocyte-derived dendritic cells</article-title>. <source>J Virol.</source> (<year>2005</year>) <volume>79</volume>:<fpage>13800</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.21.13800-13805.2005</pub-id><?supplied-pmid 16227300?><pub-id pub-id-type="pmid">16227300</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>HK</given-names></name><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Ng</surname><given-names>HY</given-names></name><name><surname>Sia</surname><given-names>SF</given-names></name><name><surname>Chan</surname><given-names>YO</given-names></name><name><surname>Luk</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells</article-title>. <source>Blood.</source> (<year>2005</year>) <volume>106</volume>:<fpage>2366</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2004-10-4166</pub-id><?supplied-pmid 15860669?><pub-id pub-id-type="pmid">15860669</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamano</surname><given-names>E</given-names></name><name><surname>Hijikata</surname><given-names>M</given-names></name><name><surname>Itoyama</surname><given-names>S</given-names></name><name><surname>Quy</surname><given-names>T</given-names></name><name><surname>Phi</surname><given-names>NC</given-names></name><name><surname>Long</surname><given-names>HT</given-names></name><etal/></person-group>. <article-title>Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population</article-title>. <source>Biochem Biophys Res Commun.</source> (<year>2005</year>) <volume>329</volume>:<fpage>1234</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2005.02.101</pub-id><?supplied-pmid 15766558?><pub-id pub-id-type="pmid">15766558</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>de Vlas</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Fontanet</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study</article-title>. <source>BMC Infect Dis.</source> (<year>2006</year>) <volume>6</volume>:<fpage>106</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2334-6-106</pub-id><?supplied-pmid 16824203?><pub-id pub-id-type="pmid">16824203</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>WC</given-names></name><name><surname>FitzGerald</surname><given-names>GA</given-names></name></person-group>. <article-title>COVID-19, microangiopathy, hemostatic activation, and complement</article-title>. <source>J Clin Invest</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1172/JCI140183</pub-id>.<?supplied-pmid 32459663?><pub-id pub-id-type="pmid">32459663</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosmann</surname><given-names>M</given-names></name></person-group>. <article-title>Complement activation during critical illness: current findings and an outlook in the era of COVID-19</article-title>. <source>Am J Respir Crit Care Med</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1164/rccm.202005-1926ED</pub-id>.<?supplied-pmid 32437622?><pub-id pub-id-type="pmid">32437622</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulasekararaj</surname><given-names>AG</given-names></name><name><surname>Lazana</surname><given-names>I</given-names></name><name><surname>Large</surname><given-names>J</given-names></name><name><surname>Posadas</surname><given-names>K</given-names></name><name><surname>Eagleton</surname><given-names>H</given-names></name><name><surname>Villajin</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Terminal complement inhibition dampens the inflammation during COVID-19</article-title>. <source>Br J Haematol</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1111/bjh.16916</pub-id>.<?supplied-pmid 32495372?><pub-id pub-id-type="pmid">32495372</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezekowitz</surname><given-names>RA</given-names></name></person-group>. <article-title>Role of the mannose-binding lectin in innate immunity</article-title>. <source>J Infect Dis.</source> (<year>2003</year>) <volume>187</volume>(<issue>Suppl. 2</issue>):<fpage>S335</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1086/374746</pub-id><?supplied-pmid 12792848?><pub-id pub-id-type="pmid">12792848</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>A</given-names></name><name><surname>Melbye</surname><given-names>M</given-names></name><name><surname>Sorensen</surname><given-names>P</given-names></name><name><surname>Homoe</surname><given-names>P</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Molbak</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood</article-title>. <source>JAMA.</source> (<year>2001</year>) <volume>285</volume>:<fpage>1316</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1001/jama.285.10.1316</pub-id><?supplied-pmid 11255386?><pub-id pub-id-type="pmid">11255386</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hibberd</surname><given-names>ML</given-names></name><name><surname>Sumiya</surname><given-names>M</given-names></name><name><surname>Summerfield</surname><given-names>JA</given-names></name><name><surname>Booy</surname><given-names>R</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name></person-group>. <article-title>Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group</article-title>. <source>Lancet.</source> (<year>1999</year>) <volume>353</volume>:<fpage>1049</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(98)08350-0</pub-id><?supplied-pmid 10199352?><pub-id pub-id-type="pmid">10199352</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Balslev</surname><given-names>U</given-names></name><name><surname>Hofmann</surname><given-names>B</given-names></name><name><surname>Pedersen</surname><given-names>C</given-names></name><name><surname>Gerstoft</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin</article-title>. <source>Lancet.</source> (<year>1997</year>) <volume>349</volume>:<fpage>236</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(96)08440-1</pub-id><?supplied-pmid 9014910?><pub-id pub-id-type="pmid">9014910</pub-id></mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ip</surname><given-names>WK</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Law</surname><given-names>HK</given-names></name><name><surname>Tso</surname><given-names>GH</given-names></name><name><surname>Kong</surname><given-names>EK</given-names></name><name><surname>Wong</surname><given-names>WH</given-names></name><etal/></person-group>. <article-title>Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection</article-title>. <source>J Infect Dis.</source> (<year>2005</year>) <volume>191</volume>:<fpage>1697</fpage>&#x02013;<lpage>704</lpage>. <pub-id pub-id-type="doi">10.1086/429631</pub-id><?supplied-pmid 15838797?><pub-id pub-id-type="pmid">15838797</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinti</surname><given-names>I</given-names></name><name><surname>Lougaris</surname><given-names>V</given-names></name><name><surname>Milito</surname><given-names>C</given-names></name><name><surname>Cinetto</surname><given-names>F</given-names></name><name><surname>Pecoraro</surname><given-names>A</given-names></name><name><surname>Mezzaroma</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>A possible role for B cells in COVID-19? lesson from patients with agammaglobulinemia</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.jaci.2020.04.013</pub-id>.<?supplied-pmid 32333914?><pub-id pub-id-type="pmid">32333914</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><etal/></person-group>. <article-title>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study</article-title>. <source>Lancet.</source> (<year>2003</year>) <volume>361</volume>:<fpage>1767</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)13412-5</pub-id><?supplied-pmid 12781535?><pub-id pub-id-type="pmid">12781535</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Arifi</surname><given-names>AA</given-names></name><name><surname>Balkhy</surname><given-names>HH</given-names></name><name><surname>Najm</surname><given-names>H</given-names></name><name><surname>Aldawood</surname><given-names>AS</given-names></name><name><surname>Ghabashi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection</article-title>. <source>Ann Intern Med.</source> (<year>2014</year>) <volume>160</volume>:<fpage>389</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.7326/M13-2486</pub-id><?supplied-pmid 24474051?><pub-id pub-id-type="pmid">24474051</pub-id></mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dauby</surname><given-names>N</given-names></name></person-group>. <article-title>Potential impact of COVID-19 in people living with HIV: experience from previous 21st century coronaviruses epidemics</article-title>. <source>AIDS.</source> (<year>2020</year>) <volume>34</volume>:<fpage>1255</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0000000000002555</pub-id><?supplied-pmid 32501850?><pub-id pub-id-type="pmid">32501850</pub-id></mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Su</surname><given-names>HC</given-names></name><name><surname>Effort</surname><given-names>CHG</given-names></name></person-group>. <article-title>A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>181</volume>:<fpage>1194</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.05.016</pub-id><?supplied-pmid 32405102?><pub-id pub-id-type="pmid">32405102</pub-id></mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matzaraki</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Zhernakova</surname><given-names>A</given-names></name></person-group>. <article-title>The MHC locus and genetic susceptibility to autoimmune and infectious diseases</article-title>. <source>Genome Biol.</source> (<year>2017</year>) <volume>18</volume>:<fpage>76</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-017-1207-1</pub-id><?supplied-pmid 28449694?><pub-id pub-id-type="pmid">28449694</pub-id></mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimarco</surname><given-names>AD</given-names></name></person-group>. <article-title>Covid-19 and ethnicity: it's too early to point to healthcare provider attitudes as a cause of poorer outcomes</article-title>. <source>BMJ.</source> (<year>2020</year>) <volume>369</volume>:<fpage>m2181</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.m2181</pub-id><?supplied-pmid 32487546?><pub-id pub-id-type="pmid">32487546</pub-id></mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassale</surname><given-names>C</given-names></name><name><surname>Gaye</surname><given-names>B</given-names></name><name><surname>Hamer</surname><given-names>M</given-names></name><name><surname>Gale</surname><given-names>CR</given-names></name><name><surname>David Batty</surname><given-names>G</given-names></name></person-group>. <article-title>Ethnic disparities in hospitalisation for COVID-19 in England: the role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study</article-title>. <source>Brain Behav Immun</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.bbi.2020.05.074</pub-id>.<?supplied-pmid 32497776?><pub-id pub-id-type="pmid">32497776</pub-id></mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galloway</surname><given-names>JB</given-names></name><name><surname>Norton</surname><given-names>S</given-names></name><name><surname>Barker</surname><given-names>RD</given-names></name><name><surname>Brookes</surname><given-names>A</given-names></name><name><surname>Carey</surname><given-names>I</given-names></name><name><surname>Clarke</surname><given-names>BD</given-names></name><etal/></person-group>
<article-title>A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: an observational cohort study</article-title>. <source>J Infect</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.jinf.2020.05.064</pub-id>.</mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandi</surname><given-names>S</given-names></name><name><surname>Nevid</surname><given-names>MZ</given-names></name><name><surname>Mahdavinia</surname><given-names>M</given-names></name></person-group>. <article-title>African American children are at higher risk for COVID-19 infection</article-title>. <source>Pediatr Allergy Immunol</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1111/pai.13298</pub-id>.<?supplied-pmid 32469426?><pub-id pub-id-type="pmid">32469426</pub-id></mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price-Haywood</surname><given-names>EG</given-names></name><name><surname>Burton</surname><given-names>J</given-names></name><name><surname>Fort</surname><given-names>D</given-names></name><name><surname>Seoane</surname><given-names>L</given-names></name></person-group>. <article-title>Hospitalization and mortality among black patients and white patients with Covid-19</article-title>. <source>N Engl J Med</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1056/NEJMsa2011686</pub-id>.<?supplied-pmid 32459916?><pub-id pub-id-type="pmid">32459916</pub-id></mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Tseng</surname><given-names>HK</given-names></name><name><surname>Trejaut</surname><given-names>JA</given-names></name><name><surname>Lee</surname><given-names>HL</given-names></name><name><surname>Loo</surname><given-names>JH</given-names></name><name><surname>Chu</surname><given-names>CC</given-names></name><etal/></person-group>. <article-title>Association of HLA class I with severe acute respiratory syndrome coronavirus infection</article-title>. <source>BMC Med Genet.</source> (<year>2003</year>) <volume>4</volume>:<fpage>9</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2350-4-9</pub-id><?supplied-pmid 12969506?><pub-id pub-id-type="pmid">12969506</pub-id></mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>YL</given-names></name><name><surname>Peiris</surname><given-names>JS</given-names></name></person-group>
<article-title>Pathogenesis of severe acute respiratory syndrome</article-title>. <source>Curr Opin Immunol.</source> (<year>2005</year>) <volume>17</volume>:<fpage>404</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2005.05.009</pub-id><pub-id pub-id-type="pmid">15950449</pub-id></mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Lau</surname><given-names>KM</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>SH</given-names></name><name><surname>Chan</surname><given-names>WY</given-names></name><name><surname>Hui</surname><given-names>PK</given-names></name><etal/></person-group>. <article-title>Association of human-leukocyte-antigen class I (B<sup>*</sup>0703) and class II (DRB1<sup>*</sup>0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome</article-title>. <source>J Infect Dis.</source> (<year>2004</year>) <volume>190</volume>:<fpage>515</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1086/421523</pub-id><?supplied-pmid 15243926?><pub-id pub-id-type="pmid">15243926</pub-id></mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Gan</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>COVID-19 infection: the perspectives on immune responses</article-title>. <source>Cell Death Differ</source>. (<year>2020</year>) <volume>27</volume>:<fpage>1451</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-020-0530-3</pub-id><?supplied-pmid 32205856?><pub-id pub-id-type="pmid">32205856</pub-id></mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Relationship between the ABO Blood Group and the COVID-19 susceptibility</article-title>. <source>medRxiv.</source> (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1101/2020.03.11.20031096</pub-id>.</mixed-citation></ref><ref id="B160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Chui</surname><given-names>CH</given-names></name><name><surname>Lau</surname><given-names>FY</given-names></name><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Ng</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>ABO blood group and susceptibility to severe acute respiratory syndrome</article-title>. <source>JAMA.</source> (<year>2005</year>) <volume>293</volume>:<fpage>1450</fpage>&#x02013;<lpage>1</lpage>. <pub-id pub-id-type="doi">10.1001/jama.293.12.1450-c</pub-id><?supplied-pmid 15784866?><pub-id pub-id-type="pmid">15784866</pub-id></mixed-citation></ref><ref id="B161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balagopal</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Thio</surname><given-names>CL</given-names></name></person-group>. <article-title>IL28B and the control of hepatitis C virus infection</article-title>. <source>Gastroenterology.</source> (<year>2010</year>) <volume>139</volume>:<fpage>1865</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2010.10.004</pub-id><?supplied-pmid 20950615?><pub-id pub-id-type="pmid">20950615</pub-id></mixed-citation></ref><ref id="B162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>FMK</given-names></name><name><surname>Freidin</surname><given-names>MB</given-names></name><name><surname>Mangino</surname><given-names>M</given-names></name><name><surname>Couvreur</surname><given-names>S</given-names></name><name><surname>Visconti</surname><given-names>A</given-names></name><name><surname>Bowyer</surname><given-names>RCE</given-names></name><etal/></person-group>
<article-title>Self-reported symptoms of covid-19 including symptoms most predictive of SARS-CoV- 2 infection, are heritable</article-title>. <source>medRxiv.</source> (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1101/2020.04.22.20072124</pub-id>.</mixed-citation></ref><ref id="B163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manthiram</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Aksentijevich</surname><given-names>I</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name></person-group>
<article-title>The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation</article-title>. <source>Nat Immunol.</source> (<year>2017</year>) <volume>18</volume>:<fpage>832</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3777</pub-id><pub-id pub-id-type="pmid">28722725</pub-id></mixed-citation></ref><ref id="B164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Jordan</surname><given-names>MB</given-names></name><name><surname>Marsh</surname><given-names>RA</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name><name><surname>Kissell</surname><given-names>D</given-names></name><name><surname>Meller</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH</article-title>. <source>Blood.</source> (<year>2011</year>) <volume>118</volume>:<fpage>5794</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2011-07-370148</pub-id><?supplied-pmid 21881043?><pub-id pub-id-type="pmid">21881043</pub-id></mixed-citation></ref><ref id="B165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heeg</surname><given-names>M</given-names></name><name><surname>Ammann</surname><given-names>S</given-names></name><name><surname>Klemann</surname><given-names>C</given-names></name><name><surname>Panning</surname><given-names>M</given-names></name><name><surname>Falcone</surname><given-names>V</given-names></name><name><surname>Hengel</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Is an infectious trigger always required for primary hemophagocytic lymphohistiocytosis? lessons from in utero and neonatal disease</article-title>. <source>Pediatr Blood Cancer.</source> (<year>2018</year>) <volume>65</volume>:<fpage>e27344</fpage>. <pub-id pub-id-type="doi">10.1002/pbc.27344</pub-id><?supplied-pmid 30070073?><pub-id pub-id-type="pmid">30070073</pub-id></mixed-citation></ref><ref id="B166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Paxton</surname><given-names>WA</given-names></name><name><surname>Wolinsky</surname><given-names>SM</given-names></name><name><surname>Neumann</surname><given-names>AU</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>The role of a mutant CCR5 allele in HIV-1 transmission and disease progression</article-title>. <source>Nat Med.</source> (<year>1996</year>) <volume>2</volume>:<fpage>1240</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/nm1196-1240</pub-id><?supplied-pmid 8898752?><pub-id pub-id-type="pmid">8898752</pub-id></mixed-citation></ref><ref id="B167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stawiski</surname><given-names>EW</given-names></name><name><surname>Diwanji</surname><given-names>D</given-names></name><name><surname>Suryamohan</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Fellouse</surname><given-names>FA</given-names></name><name><surname>Sathirapongsasuti</surname><given-names>JF</given-names></name><etal/></person-group>
<article-title>Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility</article-title>. <source>bioRxiv.</source> (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1101/2020.04.07.024752</pub-id>.</mixed-citation></ref><ref id="B168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asselta</surname><given-names>R</given-names></name><name><surname>Paraboschi</surname><given-names>EM</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Duga</surname><given-names>S</given-names></name></person-group>. <article-title>ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy</article-title>. <source>Aging.</source> (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.18632/aging.103415</pub-id>.<?supplied-pmid 32501810?><pub-id pub-id-type="pmid">32501810</pub-id></mixed-citation></ref><ref id="B169"><label>169.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>(FDA) USFDA</collab></person-group>
<source>Corona Virus Disease 2019</source>. (COVID-19) (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19">https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19</ext-link> (accessed April 10, 2020).</mixed-citation></ref><ref id="B170"><label>170.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>EMA</collab></person-group>
<source>Coronavirus Disease (COVID-19).</source> (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19">https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19</ext-link> (accessed April 10, 2020).</mixed-citation></ref><ref id="B171"><label>171.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group>
<source>&#x0201c;Solidarity&#x0201d; Clinical Trial for COVID-19 Treatments.</source> (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments</ext-link> (accessed April 5, 2020).</mixed-citation></ref><ref id="B172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group>. <article-title>Updated approaches against SARS-CoV-2</article-title>. <source>Antimicrob Agents Chemother</source>. (<year>2020</year>) <volume>64</volume>:<fpage>e00483</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00483-20</pub-id><?supplied-pmid 32205349?><pub-id pub-id-type="pmid">32205349</pub-id></mixed-citation></ref><ref id="B173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>MA</given-names></name></person-group>. <article-title>Compounds with therapeutic potential against novel respiratory 2019 coronavirus</article-title>. <source>Antimicrob Agents Chemother</source>. (<year>2020</year>) <volume>64</volume>:<fpage>e00399</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00399-20</pub-id><?supplied-pmid 32152082?><pub-id pub-id-type="pmid">32152082</pub-id></mixed-citation></ref><ref id="B174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>CJ</given-names></name><name><surname>Tchesnokov</surname><given-names>EP</given-names></name><name><surname>Feng</surname><given-names>JY</given-names></name><name><surname>Porter</surname><given-names>DP</given-names></name><name><surname>Gotte</surname><given-names>M</given-names></name></person-group>. <article-title>The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus</article-title>. <source>J Biol Chem</source>. (<year>2020</year>) <volume>295</volume>: <fpage>4773</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.AC120.013056</pub-id><?supplied-pmid 32094225?><pub-id pub-id-type="pmid">32094225</pub-id></mixed-citation></ref><ref id="B175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title>. <source>Cell Res.</source> (<year>2020</year>) <volume>30</volume>:<fpage>269</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><?supplied-pmid 32020029?><pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="B176"><label>176.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Menachery</surname><given-names>VD</given-names></name><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Case</surname><given-names>JB</given-names></name><etal/></person-group>
<article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</article-title>. <source>Sci Transl Med.</source> (<year>2017</year>) <volume>9</volume>:<fpage>eaal3653</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aal3653</pub-id><pub-id pub-id-type="pmid">28659436</pub-id></mixed-citation></ref><ref id="B177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>MK</given-names></name><name><surname>Jordan</surname><given-names>R</given-names></name><name><surname>Arvey</surname><given-names>A</given-names></name><name><surname>Sudhamsu</surname><given-names>J</given-names></name><name><surname>Shrivastava-Ranjan</surname><given-names>P</given-names></name><name><surname>Hotard</surname><given-names>AL</given-names></name><etal/></person-group>. <article-title>GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses</article-title>. <source>Sci Rep.</source> (<year>2017</year>) <volume>7</volume>:<fpage>43395</fpage>. <pub-id pub-id-type="doi">10.1038/srep43395</pub-id><?supplied-pmid 28262699?><pub-id pub-id-type="pmid">28262699</pub-id></mixed-citation></ref><ref id="B178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A</given-names></name><name><surname>Won</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title>. <source>Nat Commun.</source> (<year>2020</year>) <volume>11</volume>:<fpage>222</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-13940-6</pub-id><?supplied-pmid 31924756?><pub-id pub-id-type="pmid">31924756</pub-id></mixed-citation></ref><ref id="B179"><label>179.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>Feldmann</surname><given-names>F</given-names></name><name><surname>Cronin</surname><given-names>J</given-names></name><name><surname>Jordan</surname><given-names>R</given-names></name><name><surname>Okumura</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2020</year>) <volume>117</volume>:<fpage>6771</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1922083117</pub-id><?supplied-pmid 32054787?><pub-id pub-id-type="pmid">32054787</pub-id></mixed-citation></ref><ref id="B180"><label>180.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Du</surname><given-names>G</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>1569</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31022-9</pub-id><?supplied-pmid 32423584?><pub-id pub-id-type="pmid">32423584</pub-id></mixed-citation></ref><ref id="B181"><label>181.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Tomashek</surname><given-names>KM</given-names></name><name><surname>Dodd</surname><given-names>LE</given-names></name><name><surname>Mehta</surname><given-names>AK</given-names></name><name><surname>Zingman</surname><given-names>BS</given-names></name><name><surname>Kalil</surname><given-names>AC</given-names></name><etal/></person-group>. <article-title>Remdesivir for the treatment of Covid-19 - preliminary report</article-title>. <source>N Engl J Med</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1056/NEJMoa2007764</pub-id>.<?supplied-pmid 32445440?><pub-id pub-id-type="pmid">32445440</pub-id></mixed-citation></ref><ref id="B182"><label>182.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>JD</given-names></name><name><surname>Lye</surname><given-names>DCB</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name><name><surname>Marks</surname><given-names>KM</given-names></name><name><surname>Bruno</surname><given-names>R</given-names></name><name><surname>Montejano</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Remdesivir for 5 or 10 days in patients with severe Covid-19</article-title>. <source>N Engl J Med</source>. (<year>2020</year>). <pub-id pub-id-type="doi">10.1056/NEJMoa2015301</pub-id></mixed-citation></ref><ref id="B183"><label>183.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antinori</surname><given-names>S</given-names></name><name><surname>Cossu</surname><given-names>MV</given-names></name><name><surname>Ridolfo</surname><given-names>AL</given-names></name><name><surname>Rech</surname><given-names>R</given-names></name><name><surname>Bonazzetti</surname><given-names>C</given-names></name><name><surname>Pagani</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status</article-title>. <source>Pharmacol Res.</source> (<year>2020</year>) <volume>158</volume>:<fpage>104899</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2020.104899</pub-id><?supplied-pmid 32407959?><pub-id pub-id-type="pmid">32407959</pub-id></mixed-citation></ref><ref id="B184"><label>184.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>JF</given-names></name><name><surname>Azhar</surname><given-names>EI</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group>. <article-title>Coronaviruses - drug discovery and therapeutic options</article-title>. <source>Nat Rev Drug Discov.</source> (<year>2016</year>) <volume>15</volume>:<fpage>327</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2015.37</pub-id><?supplied-pmid 26868298?><pub-id pub-id-type="pmid">26868298</pub-id></mixed-citation></ref><ref id="B185"><label>185.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choy</surname><given-names>KT</given-names></name><name><surname>Yin-Lam Wong</surname><given-names>A</given-names></name><name><surname>Kaewpreedee</surname><given-names>P</given-names></name><name><surname>Sia</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Yan Hui</surname><given-names>KP</given-names></name><etal/></person-group>. <article-title>Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro</article-title>. <source>Antiviral Res</source>. (<year>2020</year>) <volume>2020</volume>:<fpage>104786</fpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104786</pub-id><?supplied-pmid 32251767?><pub-id pub-id-type="pmid">32251767</pub-id></mixed-citation></ref><ref id="B186"><label>186.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Cui</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name><etal/></person-group>. <article-title><italic>In vitro</italic> antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2)</article-title>. <source>Clin Infect Dis</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id>.<?supplied-pmid 32150618?><pub-id pub-id-type="pmid">32150618</pub-id></mixed-citation></ref><ref id="B187"><label>187.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</article-title>. <source>Cell Discov.</source> (<year>2020</year>) <volume>6</volume>:<fpage>16</fpage>. <pub-id pub-id-type="doi">10.1038/s41421-020-0156-0</pub-id><?supplied-pmid 32194981?><pub-id pub-id-type="pmid">32194981</pub-id></mixed-citation></ref><ref id="B188"><label>188.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>382</volume>:<fpage>1787</fpage>&#x02013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2008043</pub-id><?supplied-pmid 32187464?><pub-id pub-id-type="pmid">32187464</pub-id></mixed-citation></ref><ref id="B189"><label>189.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borba</surname><given-names>MGS</given-names></name><name><surname>Val</surname><given-names>FFA</given-names></name><name><surname>Sampaio</surname><given-names>VS</given-names></name><name><surname>Alexandre</surname><given-names>MAA</given-names></name><name><surname>Melo</surname><given-names>GC</given-names></name><name><surname>Brito</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial</article-title>. <source>JAMA Netw Open.</source> (<year>2020</year>) <volume>3</volume>:<fpage>e208857</fpage>
<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.8857</pub-id></mixed-citation></ref><ref id="B190"><label>190.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahevas</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>VT</given-names></name><name><surname>Roumier</surname><given-names>M</given-names></name><name><surname>Chabrol</surname><given-names>A</given-names></name><name><surname>Paule</surname><given-names>R</given-names></name><name><surname>Guillaud</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data</article-title>. <source>BMJ.</source> (<year>2020</year>) <volume>369</volume>:<fpage>m1844</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.m1844</pub-id><?supplied-pmid 32409486?><pub-id pub-id-type="pmid">32409486</pub-id></mixed-citation></ref><ref id="B191"><label>191.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulware</surname><given-names>DR</given-names></name><name><surname>Pullen</surname><given-names>MF</given-names></name><name><surname>Bangdiwala</surname><given-names>AS</given-names></name><name><surname>Pastick</surname><given-names>KA</given-names></name><name><surname>Lofgren</surname><given-names>SM</given-names></name><name><surname>Okafor</surname><given-names>EC</given-names></name><etal/></person-group>
<article-title>A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19</article-title>. <source>N Engl J Med</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1056/NEJMoa2016638</pub-id>.</mixed-citation></ref><ref id="B192"><label>192.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geleris</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Platt</surname><given-names>J</given-names></name><name><surname>Zucker</surname><given-names>J</given-names></name><name><surname>Baldwin</surname><given-names>M</given-names></name><name><surname>Hripcsak</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Observational study of hydroxychloroquine in hospitalized patients with Covid-19</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>382</volume>:<fpage>2411</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2012410</pub-id><?supplied-pmid 32379955?><pub-id pub-id-type="pmid">32379955</pub-id></mixed-citation></ref><ref id="B193"><label>193.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>ES</given-names></name><name><surname>Dufort</surname><given-names>EM</given-names></name><name><surname>Udo</surname><given-names>T</given-names></name><name><surname>Wilberschied</surname><given-names>LA</given-names></name><name><surname>Kumar</surname><given-names>J</given-names></name><name><surname>Tesoriero</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State</article-title>. <source>JAMA</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1001/jama.2020.8630</pub-id>.</mixed-citation></ref><ref id="B194"><label>194.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P</given-names></name><name><surname>Lagier</surname><given-names>JC</given-names></name><name><surname>Parola</surname><given-names>P</given-names></name><name><surname>Hoang</surname><given-names>VT</given-names></name><name><surname>Meddeb</surname><given-names>L</given-names></name><name><surname>Mailhe</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title>. <source>Int J Antimicrob Agents</source>. (<year>2020</year>) <volume>2020</volume>:<fpage>105949</fpage>
<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id></mixed-citation></ref><ref id="B195"><label>195.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Pang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Treating COVID-19 with chloroquine</article-title>. <source>J Mol Cell Biol.</source> (<year>2020</year>) <volume>12</volume>:<fpage>322</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1093/jmcb/mjaa014</pub-id><pub-id pub-id-type="pmid">32236562</pub-id></mixed-citation></ref><ref id="B196"><label>196.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehra</surname><given-names>MR</given-names></name><name><surname>Desai</surname><given-names>SS</given-names></name><name><surname>Ruschitzka</surname><given-names>F</given-names></name><name><surname>Patel</surname><given-names>AN</given-names></name></person-group>
<article-title>Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis</article-title>. <source>Lancet</source>. (<year>2020</year>). <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31180-6</pub-id></mixed-citation></ref><ref id="B197"><label>197.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group>
<source>WHO Director-General's Opening Remarks at the Media Briefing on COVID-19.</source> (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-&#x02212;25-may-2020">https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-&#x02212;25-may-2020</ext-link> (accessed May 25, 2020).</mixed-citation></ref><ref id="B198"><label>198.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group>
<source>WHO Director-General's Opening Remarks at the Media Briefing on COVID-19.</source> (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-&#x02212;03-june-2020">https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-&#x02212;03-june-2020</ext-link> (accessed June 3, 2020).</mixed-citation></ref><ref id="B199"><label>199.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Vedantham</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Agudelo</surname><given-names>J</given-names></name><name><surname>Carrion</surname><given-names>R</given-names><suffix>Jr.</suffix></name><etal/></person-group>. <article-title>Protease inhibitors targeting coronavirus and filovirus entry</article-title>. <source>Antiviral Res.</source> (<year>2015</year>) <volume>116</volume>:<fpage>76</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.01.011</pub-id><?supplied-pmid 25666761?><pub-id pub-id-type="pmid">25666761</pub-id></mixed-citation></ref><ref id="B200"><label>200.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>FOIPAN</collab></person-group>
<source>Camostat Mesilate Tablets Information Sheet</source>. <publisher-loc>Osaka</publisher-loc>: <publisher-name>Ono Pharmaceutical CO., Ltd</publisher-name>.</mixed-citation></ref><ref id="B201"><label>201.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>ML</given-names></name><name><surname>Nuttall</surname><given-names>J</given-names></name><name><surname>Hart</surname><given-names>PA</given-names></name></person-group>. <article-title>A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC)</article-title>. <source>Trials.</source> (<year>2019</year>) <volume>20</volume>:<fpage>501</fpage>. <pub-id pub-id-type="doi">10.1186/s13063-019-3606-y</pub-id><?supplied-pmid 31412955?><pub-id pub-id-type="pmid">31412955</pub-id></mixed-citation></ref><ref id="B202"><label>202.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Clinicaltrials.gov</collab></person-group>
<source>The Impact of Camostat Mesilate on COVID-19 Infection (CamoCO-19)</source>. NCT04321096: Clinicaltrials.gov; (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04321096?term=Camostat+mesylate&#x00026;draw=2&#x00026;rank=1">https://clinicaltrials.gov/ct2/show/NCT04321096?term=Camostat+mesylate&#x00026;draw=2&#x00026;rank=1</ext-link> (accessed April 16, 2020).</mixed-citation></ref><ref id="B203"><label>203.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toniati</surname><given-names>P</given-names></name><name><surname>Piva</surname><given-names>S</given-names></name><name><surname>Cattalini</surname><given-names>M</given-names></name><name><surname>Garrafa</surname><given-names>E</given-names></name><name><surname>Regola</surname><given-names>F</given-names></name><name><surname>Castelli</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy</article-title>. <source>Autoimmun Rev.</source> (<year>2020</year>) <volume>19</volume>:<fpage>102568</fpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2020.102568pagebreak</pub-id><?supplied-pmid 32376398?><pub-id pub-id-type="pmid">32376398</pub-id></mixed-citation></ref><ref id="B204"><label>204.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Fu</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Effective treatment of severe COVID-19 patients with tocilizumab</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2020</year>) <volume>117</volume>:<fpage>10970</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2005615117</pub-id><?supplied-pmid 32350134?><pub-id pub-id-type="pmid">32350134</pub-id></mixed-citation></ref><ref id="B205"><label>205.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Campochiaro</surname><given-names>C</given-names></name><name><surname>Della-Torre</surname><given-names>E</given-names></name><name><surname>Ripa</surname><given-names>M</given-names></name><name><surname>Canetti</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study</article-title>. <source>Lancet Rheumatol.</source> (<year>2020</year>) <volume>2</volume>:<fpage>e325</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/S2665-9913(20)30127-2</pub-id><?supplied-pmid 32501454?><pub-id pub-id-type="pmid">32501454</pub-id></mixed-citation></ref><ref id="B206"><label>206.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huet</surname><given-names>T</given-names></name><name><surname>Beaussier</surname><given-names>H</given-names></name><name><surname>Voisin</surname><given-names>O</given-names></name><name><surname>Jouveshomme</surname><given-names>S</given-names></name><name><surname>Dauriat</surname><given-names>G</given-names></name><name><surname>Lazareth</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Anakinra for severe forms of COVID-19: a cohort study</article-title>. <source>Lancet</source>. (<year>2020</year>) <volume>2</volume>:<fpage>e393</fpage>&#x02013;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1016/S2665-9913(20)30164-8</pub-id></mixed-citation></ref><ref id="B207"><label>207.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimopoulos</surname><given-names>G</given-names></name><name><surname>de Mast</surname><given-names>Q</given-names></name><name><surname>Markou</surname><given-names>N</given-names></name><name><surname>Theodorakopoulou</surname><given-names>M</given-names></name><name><surname>Komnos</surname><given-names>A</given-names></name><name><surname>Mouktaroudi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis</article-title>. <source>Cell Host Microbe</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.chom.2020.05.007</pub-id>.<?supplied-pmid 32411313?><pub-id pub-id-type="pmid">32411313</pub-id></mixed-citation></ref><ref id="B208"><label>208.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rilinger</surname><given-names>J</given-names></name><name><surname>Kern</surname><given-names>WV</given-names></name><name><surname>Duerschmied</surname><given-names>D</given-names></name><name><surname>Supady</surname><given-names>A</given-names></name><name><surname>Bode</surname><given-names>C</given-names></name><name><surname>Staudacher</surname><given-names>DL</given-names></name><etal/></person-group>. <article-title>A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial</article-title>. <source>Trials.</source> (<year>2020</year>) <volume>21</volume>:<fpage>470</fpage>. <pub-id pub-id-type="doi">10.1186/s13063-020-04447-3</pub-id><?supplied-pmid 32493514?><pub-id pub-id-type="pmid">32493514</pub-id></mixed-citation></ref><ref id="B209"><label>209.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maes</surname><given-names>B</given-names></name><name><surname>Bosteels</surname><given-names>C</given-names></name><name><surname>De Leeuw</surname><given-names>E</given-names></name><name><surname>Declercq</surname><given-names>J</given-names></name><name><surname>Van Damme</surname><given-names>K</given-names></name><name><surname>Delporte</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial</article-title>. <source>Trials.</source> (<year>2020</year>) <volume>21</volume>:<fpage>468</fpage>
<pub-id pub-id-type="doi">10.1186/s13063-020-04453-5</pub-id><pub-id pub-id-type="pmid">32493441</pub-id></mixed-citation></ref><ref id="B210"><label>210.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvarani</surname><given-names>C</given-names></name><name><surname>Bajocchi</surname><given-names>G</given-names></name><name><surname>Mancuso</surname><given-names>P</given-names></name><name><surname>Galli</surname><given-names>E</given-names></name><name><surname>Muratore</surname><given-names>F</given-names></name><name><surname>Boiardi</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study</article-title>. <source>Ann Rheum Dis</source>. (<year>2020</year>) <volume>79</volume>:<fpage>986</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2020-217903</pub-id><?supplied-pmid 32467245?><pub-id pub-id-type="pmid">32467245</pub-id></mixed-citation></ref><ref id="B211"><label>211.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cugno</surname><given-names>M</given-names></name><name><surname>Meroni</surname><given-names>PL</given-names></name><name><surname>Gualtierotti</surname><given-names>R</given-names></name><name><surname>Griffini</surname><given-names>S</given-names></name><name><surname>Grovetti</surname><given-names>E</given-names></name><name><surname>Torri</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Complement activation in patients with COVID-19: A novel therapeutic target</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2020</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.jaci.2020.05.006</pub-id>.<?supplied-pmid 32417135?><pub-id pub-id-type="pmid">32417135</pub-id></mixed-citation></ref><ref id="B212"><label>212.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group>
<source>Blueprint, Landscape analysis of therapeutics as 21st March 2020.</source> (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1">https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1</ext-link>) (accessed April 11, 2020).</mixed-citation></ref><ref id="B213"><label>213.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group>
<source>DRAFT landscape of COVID-19 candidate vaccines.</source> (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1">https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1</ext-link> (accessed April 12, 2020).</mixed-citation></ref></ref-list></back></article>